JP2013532692A - Ampk活性化複素環化合物およびその使用方法 - Google Patents
Ampk活性化複素環化合物およびその使用方法 Download PDFInfo
- Publication number
- JP2013532692A JP2013532692A JP2013522013A JP2013522013A JP2013532692A JP 2013532692 A JP2013532692 A JP 2013532692A JP 2013522013 A JP2013522013 A JP 2013522013A JP 2013522013 A JP2013522013 A JP 2013522013A JP 2013532692 A JP2013532692 A JP 2013532692A
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- piperidin
- picolinamide
- alkyl
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 129
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 title claims abstract description 30
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 title claims abstract description 30
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 668
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- 201000010099 disease Diseases 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Chemical class 0.000 claims abstract description 31
- 230000037361 pathway Effects 0.000 claims abstract description 18
- 230000002503 metabolic effect Effects 0.000 claims abstract description 8
- -1 alkyl Carbon Chemical compound 0.000 claims description 570
- 125000000217 alkyl group Chemical group 0.000 claims description 233
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 100
- 125000004122 cyclic group Chemical group 0.000 claims description 95
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 94
- 150000003839 salts Chemical class 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 82
- 229910052799 carbon Inorganic materials 0.000 claims description 78
- 125000001072 heteroaryl group Chemical group 0.000 claims description 75
- 150000001204 N-oxides Chemical class 0.000 claims description 71
- 239000012453 solvate Substances 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 66
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 57
- 125000003118 aryl group Chemical group 0.000 claims description 47
- 229940002612 prodrug Drugs 0.000 claims description 46
- 239000000651 prodrug Substances 0.000 claims description 46
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 32
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 32
- 229940106189 ceramide Drugs 0.000 claims description 32
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 32
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 32
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 125000001188 haloalkyl group Chemical group 0.000 claims description 27
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 26
- 125000005549 heteroarylene group Chemical group 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 23
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 125000000732 arylene group Chemical group 0.000 claims description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 150000004665 fatty acids Chemical class 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 14
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 150000003254 radicals Chemical class 0.000 claims description 12
- 102000004201 Ceramidases Human genes 0.000 claims description 11
- 108090000751 Ceramidases Proteins 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 208000028867 ischemia Diseases 0.000 claims description 11
- 125000002950 monocyclic group Chemical group 0.000 claims description 11
- 230000036542 oxidative stress Effects 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 206010021143 Hypoxia Diseases 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 230000007954 hypoxia Effects 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 5
- 229920002527 Glycogen Polymers 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 5
- 229940096919 glycogen Drugs 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000004190 glucose uptake Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 4
- 230000004898 mitochondrial function Effects 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 210000001087 myotubule Anatomy 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010061216 Infarction Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000010428 Muscle Weakness Diseases 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 208000002033 Myoclonus Diseases 0.000 claims description 3
- KILULKZXXSWNCI-UHFFFAOYSA-N N-[4-(4-cyanophenoxy)cyclohexyl]-5-[4-(4-fluorobenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 KILULKZXXSWNCI-UHFFFAOYSA-N 0.000 claims description 3
- BZCVQNXMJJLXPG-UHFFFAOYSA-N N-[4-(4-cyanophenoxy)cyclohexyl]-5-[4-(4-fluorophenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 BZCVQNXMJJLXPG-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010053476 Traumatic haemorrhage Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010053648 Vascular occlusion Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 208000008445 altitude sickness Diseases 0.000 claims description 3
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 3
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims description 3
- 230000007574 infarction Effects 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 230000009826 neoplastic cell growth Effects 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 3
- BKCJRBLXKYEYHK-UHFFFAOYSA-N 1-[(4-cyanophenyl)methyl]-n-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]piperidine-4-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC(=O)C3CCN(CC=4C=CC(=CC=4)C#N)CC3)=CC=2)CC1 BKCJRBLXKYEYHK-UHFFFAOYSA-N 0.000 claims description 2
- PYLAIZRZOYDMDH-UHFFFAOYSA-N 2-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-n-[1-(4-cyanophenyl)piperidin-4-yl]pyridine-2,5-dicarboxamide Chemical compound C=1C=C(C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)N=CC=1C(=O)NC(CC1)CCN1C1=CC=C(C#N)C=C1 PYLAIZRZOYDMDH-UHFFFAOYSA-N 0.000 claims description 2
- DENRPACRNJYZDG-UHFFFAOYSA-N 2-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-n-[2-(4-fluorophenoxy)ethyl]pyridine-2,5-dicarboxamide Chemical compound C1=CC(F)=CC=C1OCCNC(=O)C1=CC=C(C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)N=C1 DENRPACRNJYZDG-UHFFFAOYSA-N 0.000 claims description 2
- NAUIMQDUCLBJRJ-UHFFFAOYSA-N 2-n-[2-[(4-cyanophenyl)methyl]-3,4-dihydro-1h-isoquinolin-7-yl]-5-n-[(4-fluorophenyl)methyl]pyridine-2,5-dicarboxamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C(C(=O)NC=2C=C3CN(CC=4C=CC(=CC=4)C#N)CCC3=CC=2)N=C1 NAUIMQDUCLBJRJ-UHFFFAOYSA-N 0.000 claims description 2
- OLOFHQKCBQKIAJ-UHFFFAOYSA-N 4-[[2-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]-2,8-diazaspiro[4.5]decan-8-yl]methyl]benzonitrile Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)N2CC3(CC2)CCN(CC=2C=CC(=CC=2)C#N)CC3)CC1 OLOFHQKCBQKIAJ-UHFFFAOYSA-N 0.000 claims description 2
- AUSCOAAXXZHOLH-UHFFFAOYSA-N 4-[[4-[[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]amino]piperidin-1-yl]methyl]benzonitrile Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC3CCN(CC=4C=CC(=CC=4)C#N)CC3)=CC=2)CC1 AUSCOAAXXZHOLH-UHFFFAOYSA-N 0.000 claims description 2
- GUOFMHPMAHVMLC-UHFFFAOYSA-N 4-[[8-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carbonyl]-2,8-diazaspiro[4.5]decan-2-yl]methyl]benzonitrile Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)N2CCC3(CN(CC=4C=CC(=CC=4)C#N)CC3)CC2)CC1 GUOFMHPMAHVMLC-UHFFFAOYSA-N 0.000 claims description 2
- ISSLZKSSYLRMSG-JDXGNMNLSA-N 5-[(3S,4S)-4-(4-cyanophenoxy)-3-fluoropiperidine-1-carbonyl]-N-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound O([C@H]1CCN(C[C@@H]1F)C(=O)C=1C=NC(=CC=1)C(=O)NC1CCN(CC=2C=CC(=CC=2)C#N)CC1)C1=CC=C(C#N)C=C1 ISSLZKSSYLRMSG-JDXGNMNLSA-N 0.000 claims description 2
- HVGKNJVYYFTFOB-UHFFFAOYSA-N 5-[3-(4-cyanophenoxy)-8-azabicyclo[3.2.1]octane-8-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2C3CCC2CC(C3)OC=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 HVGKNJVYYFTFOB-UHFFFAOYSA-N 0.000 claims description 2
- OALQOHPDGYLZQW-UHFFFAOYSA-N 5-[3-(4-cyanophenoxy)azetidine-1-carbonyl]-n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound FC1=CC(F)=CC(CN2CCC(CC2)NC(=O)C=2N=CC(=CC=2)C(=O)N2CC(C2)OC=2C=CC(=CC=2)C#N)=C1 OALQOHPDGYLZQW-UHFFFAOYSA-N 0.000 claims description 2
- PYKNAWSLPPFUNW-UHFFFAOYSA-N 5-[3-(4-cyanophenoxy)piperidin-1-yl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(N2CC(CCC2)OC=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 PYKNAWSLPPFUNW-UHFFFAOYSA-N 0.000 claims description 2
- BYINZUBHGSJUSR-UHFFFAOYSA-N 5-[3-(4-cyanophenyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl]-n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound FC1=CC(F)=CC(CN2CCC(CC2)NC(=O)C=2N=CC(=CC=2)C(=O)N2CC=3N(C(=NN=3)C=3C=CC(=CC=3)C#N)CC2)=C1 BYINZUBHGSJUSR-UHFFFAOYSA-N 0.000 claims description 2
- DTDPXJTYCFTEEW-UHFFFAOYSA-N 5-[4-(3,4-difluorophenoxy)piperidine-1-carbonyl]-n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound FC1=CC(F)=CC(CN2CCC(CC2)NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=C(F)C(F)=CC=2)=C1 DTDPXJTYCFTEEW-UHFFFAOYSA-N 0.000 claims description 2
- FGBIWVHUOKXSKR-UHFFFAOYSA-N 5-[4-(3-cyanophenoxy)piperidine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=C(C=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 FGBIWVHUOKXSKR-UHFFFAOYSA-N 0.000 claims description 2
- JVERBNBWKSQTRY-UHFFFAOYSA-N 5-[4-(4-chlorobenzoyl)piperidin-1-yl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)C1CCN(C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 JVERBNBWKSQTRY-UHFFFAOYSA-N 0.000 claims description 2
- VHMVZBCHWOEJTQ-UHFFFAOYSA-N 5-[4-(4-cyano-2-methoxyphenoxy)piperidin-1-yl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound COC1=CC(C#N)=CC=C1OC1CCN(C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 VHMVZBCHWOEJTQ-UHFFFAOYSA-N 0.000 claims description 2
- KESKUMQAYVXYTP-UHFFFAOYSA-N 5-[4-(4-cyanobenzoyl)piperidine-1-carbonyl]-N-[4-(4-fluorophenoxy)cyclohexyl]pyridine-2-carboxamide Chemical compound Fc1ccc(OC2CCC(CC2)NC(=O)c2ccc(cn2)C(=O)N2CCC(CC2)C(=O)c2ccc(cc2)C#N)cc1 KESKUMQAYVXYTP-UHFFFAOYSA-N 0.000 claims description 2
- RMRAPVQTYURKPZ-UHFFFAOYSA-N 5-[4-(4-cyanophenoxy)piperidin-1-yl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(N2CCC(CC2)OC=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 RMRAPVQTYURKPZ-UHFFFAOYSA-N 0.000 claims description 2
- ZSPDVYPDGBHLED-UHFFFAOYSA-N 5-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[2-(4-fluorophenoxy)ethyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OCCNC(=O)C1=CC=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)C=N1 ZSPDVYPDGBHLED-UHFFFAOYSA-N 0.000 claims description 2
- XZNBTHWUHWCAHY-UHFFFAOYSA-N 5-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[4-(4-fluorophenoxy)cyclohexyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 XZNBTHWUHWCAHY-UHFFFAOYSA-N 0.000 claims description 2
- ZSDOZPPRAYGYEU-UHFFFAOYSA-N 5-[4-[(4-cyanophenyl)methyl]piperazine-1-carbonyl]-n-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 ZSDOZPPRAYGYEU-UHFFFAOYSA-N 0.000 claims description 2
- DKZIWVLUHXKRHI-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(2-phenylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1 DKZIWVLUHXKRHI-UHFFFAOYSA-N 0.000 claims description 2
- CQQMMXMEYNOOTM-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(3-phenoxyphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=C(OC=3C=CC=CC=3)C=CC=2)CC1 CQQMMXMEYNOOTM-UHFFFAOYSA-N 0.000 claims description 2
- DEAYGZRRXFNGTA-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(3-phenylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=C(C=CC=2)C=2C=CC=CC=2)CC1 DEAYGZRRXFNGTA-UHFFFAOYSA-N 0.000 claims description 2
- VHXPMMSGAZXAOF-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(4-morpholin-4-ylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)N2CCOCC2)CC1 VHXPMMSGAZXAOF-UHFFFAOYSA-N 0.000 claims description 2
- KFWUZHLIUCMOPR-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(4-phenoxyphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(OC=3C=CC=CC=3)=CC=2)CC1 KFWUZHLIUCMOPR-UHFFFAOYSA-N 0.000 claims description 2
- IKKVPXFGSRKNJV-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(4-phenylmethoxyphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 IKKVPXFGSRKNJV-UHFFFAOYSA-N 0.000 claims description 2
- PRJISZJJPGFGHG-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(4-phenylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 PRJISZJJPGFGHG-UHFFFAOYSA-N 0.000 claims description 2
- BJRZKIVEUFLPAU-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(4-thiophen-3-ylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C2=CSC=C2)CC1 BJRZKIVEUFLPAU-UHFFFAOYSA-N 0.000 claims description 2
- ANLDAUPWGMIDKB-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(1h-pyrrol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C2=CNC=C2)CC1 ANLDAUPWGMIDKB-UHFFFAOYSA-N 0.000 claims description 2
- WDGGQCRMJXHVAD-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(3-methoxyphenoxy)phenyl]pyridine-2-carboxamide Chemical compound COC1=CC=CC(OC=2C=CC(NC(=O)C=3N=CC(=CC=3)C(=O)N3CCN(CC=4C=CC(F)=CC=4)CC3)=CC=2)=C1 WDGGQCRMJXHVAD-UHFFFAOYSA-N 0.000 claims description 2
- CBGKMLBDMVQWBH-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(3-methylphenoxy)phenyl]pyridine-2-carboxamide Chemical compound CC1=CC=CC(OC=2C=CC(NC(=O)C=3N=CC(=CC=3)C(=O)N3CCN(CC=4C=CC(F)=CC=4)CC3)=CC=2)=C1 CBGKMLBDMVQWBH-UHFFFAOYSA-N 0.000 claims description 2
- RDGQWELXIWGGAA-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(4-methoxyphenoxy)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)C=N1 RDGQWELXIWGGAA-UHFFFAOYSA-N 0.000 claims description 2
- DVMILXSBZSNOPF-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(4-methoxyphenyl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)C=N1 DVMILXSBZSNOPF-UHFFFAOYSA-N 0.000 claims description 2
- RMWNMWQMKJQMNP-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(4-methylphenoxy)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)C=N1 RMWNMWQMKJQMNP-UHFFFAOYSA-N 0.000 claims description 2
- QSOJIZDCHOEGLA-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(4-methylpiperazin-1-yl)phenyl]pyridine-2-carboxamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)C=N1 QSOJIZDCHOEGLA-UHFFFAOYSA-N 0.000 claims description 2
- GAYRGESOQUQOTJ-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-(4-nitrophenyl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(C=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)C=N1 GAYRGESOQUQOTJ-UHFFFAOYSA-N 0.000 claims description 2
- RBSXAXHVCUKMIZ-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[4-[4-(trifluoromethyl)phenyl]phenyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)CC1 RBSXAXHVCUKMIZ-UHFFFAOYSA-N 0.000 claims description 2
- KJSYIIMVXXSKOC-UHFFFAOYSA-N 5-[4-fluoro-4-(4-fluorobenzoyl)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(F)(CC2)C(=O)C=2C=CC(F)=CC=2)C=N1 KJSYIIMVXXSKOC-UHFFFAOYSA-N 0.000 claims description 2
- HFTJORLORZXKEZ-UHFFFAOYSA-N 6-[4-(3-acetamidophenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound CC(=O)NC1=CC=CC(OC2CCN(CC2)C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)=C1 HFTJORLORZXKEZ-UHFFFAOYSA-N 0.000 claims description 2
- NSZYFVPQFQAZIY-UHFFFAOYSA-N 6-[4-(4-cyanophenoxy)piperidin-1-yl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridazine-3-carboxamide Chemical compound C=1C=C(N2CCC(CC2)OC=2C=CC(=CC=2)C#N)N=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 NSZYFVPQFQAZIY-UHFFFAOYSA-N 0.000 claims description 2
- ZXOKHOODFVNZIC-UHFFFAOYSA-N 6-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)N=CC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 ZXOKHOODFVNZIC-UHFFFAOYSA-N 0.000 claims description 2
- ODCYZWPLGOHHLR-UHFFFAOYSA-N 6-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[4-(4-fluorophenoxy)cyclohexyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 ODCYZWPLGOHHLR-UHFFFAOYSA-N 0.000 claims description 2
- BOMYFXTYBRETRO-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[1-(4-methylsulfonylphenyl)piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 BOMYFXTYBRETRO-UHFFFAOYSA-N 0.000 claims description 2
- OUYBMULCCUWUIY-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 OUYBMULCCUWUIY-UHFFFAOYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 2
- CGHXVKSEPXSOKT-UHFFFAOYSA-N N-[1-(4-cyanophenoxy)piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound COc1ccc(cc1)C(=O)C1CCN(CC1)C(=O)c1ccc(cn1)C(=O)NC1CCN(CC1)Oc1ccc(cc1)C#N CGHXVKSEPXSOKT-UHFFFAOYSA-N 0.000 claims description 2
- PBWMNTCCVDFBFE-UHFFFAOYSA-N N-[1-(4-fluorophenoxy)piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound COc1ccc(cc1)C(=O)C1CCN(CC1)C(=O)c1ccc(cn1)C(=O)NC1CCN(CC1)Oc1ccc(F)cc1 PBWMNTCCVDFBFE-UHFFFAOYSA-N 0.000 claims description 2
- GIQKDCHBWREEQP-UHFFFAOYSA-N N-[4-(4-cyanophenoxy)cyclohexyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 GIQKDCHBWREEQP-UHFFFAOYSA-N 0.000 claims description 2
- SZJATISBSPFCJL-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-(3-phenylanilino)pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC=3C=C(C=CC=3)C=3C=CC=CC=3)=CC=2)CC1 SZJATISBSPFCJL-UHFFFAOYSA-N 0.000 claims description 2
- QSFRHVLXMAFXQR-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-(3-phenylmethoxyphenyl)pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C=2C=C(OCC=3C=CC=CC=3)C=CC=2)CC1 QSFRHVLXMAFXQR-UHFFFAOYSA-N 0.000 claims description 2
- SCZKOAZZRCYNFT-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-(4-phenoxyanilino)pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC=3C=CC(OC=4C=CC=CC=4)=CC=3)=CC=2)CC1 SCZKOAZZRCYNFT-UHFFFAOYSA-N 0.000 claims description 2
- LFRKRHVIDSBBJO-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-(4-phenylmethoxyphenyl)pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 LFRKRHVIDSBBJO-UHFFFAOYSA-N 0.000 claims description 2
- HOVNBOLMJBLKSZ-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-(4-phenylpiperazine-1-carbonyl)pyridin-2-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=C(C=CC=2)C(=O)N2CCN(CC2)C=2C=CC=CC=2)CC1 HOVNBOLMJBLKSZ-UHFFFAOYSA-N 0.000 claims description 2
- VPTJAMUGKWOOJY-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-[[1-[(4-fluorophenyl)methyl]pyrazol-4-yl]amino]pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC3=CN(CC=4C=CC(F)=CC=4)N=C3)=CC=2)CC1 VPTJAMUGKWOOJY-UHFFFAOYSA-N 0.000 claims description 2
- PXCXFGLKFBBGMD-UHFFFAOYSA-N [6-(4-benzylanilino)pyridin-3-yl]-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC=3C=CC(CC=4C=CC=CC=4)=CC=3)=CC=2)CC1 PXCXFGLKFBBGMD-UHFFFAOYSA-N 0.000 claims description 2
- ZCVDBEVZVHBBJC-UHFFFAOYSA-N [6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-3-yl]-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 ZCVDBEVZVHBBJC-UHFFFAOYSA-N 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- QBCOHMKIOZPEPA-UHFFFAOYSA-N ethyl 4-[1-[6-[[1-[(4-cyanophenyl)methyl]piperidin-4-yl]carbamoyl]pyridine-3-carbonyl]piperidin-4-yl]oxybenzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 QBCOHMKIOZPEPA-UHFFFAOYSA-N 0.000 claims description 2
- 230000037080 exercise endurance Effects 0.000 claims description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- 230000001146 hypoxic effect Effects 0.000 claims description 2
- PGYYJEYPHRIKEA-UHFFFAOYSA-N n-(1-benzoylpiperidin-4-yl)-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC2)C(=O)C=2C=CC=CC=2)CC1 PGYYJEYPHRIKEA-UHFFFAOYSA-N 0.000 claims description 2
- IVEYKDVYNMMLFY-UHFFFAOYSA-N n-(4-benzoylphenyl)-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)CC1 IVEYKDVYNMMLFY-UHFFFAOYSA-N 0.000 claims description 2
- VRFSYYBIXZHSAS-UHFFFAOYSA-N n-(4-benzylphenyl)-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(CC=3C=CC=CC=3)=CC=2)CC1 VRFSYYBIXZHSAS-UHFFFAOYSA-N 0.000 claims description 2
- MTYUQDCNXVHHAR-UHFFFAOYSA-N n-(4-bromophenyl)-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(Br)=CC=2)CC1 MTYUQDCNXVHHAR-UHFFFAOYSA-N 0.000 claims description 2
- XSTWHJANPVSKRP-FQLXRVMXSA-N n-[(3r,4r)-1-[(4-cyano-3-fluorophenyl)methyl]-3-fluoropiperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@@H](CN(CC=3C=C(F)C(C#N)=CC=3)CC2)F)CC1 XSTWHJANPVSKRP-FQLXRVMXSA-N 0.000 claims description 2
- QECRHJAQOQEILO-IZZNHLLZSA-N n-[(3s,4r)-3-fluoro-1-[(2-methyl-1,3-thiazol-4-yl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@H](CN(CC=3N=C(C)SC=3)CC2)F)CC1 QECRHJAQOQEILO-IZZNHLLZSA-N 0.000 claims description 2
- HJLLFICFQXAIAT-IZZNHLLZSA-N n-[(3s,4r)-3-fluoro-1-[(5-methyl-1,2-oxazol-3-yl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@H](CN(CC3=NOC(C)=C3)CC2)F)CC1 HJLLFICFQXAIAT-IZZNHLLZSA-N 0.000 claims description 2
- IGRUICVFLYEORO-UHFFFAOYSA-N n-[(4-cyanophenyl)methyl]-3-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C=2C=C(C=CC=2)C(=O)NCC=2C=CC(=CC=2)C#N)CC1 IGRUICVFLYEORO-UHFFFAOYSA-N 0.000 claims description 2
- PTFCCBDWBUWRTB-UHFFFAOYSA-N n-[(4-cyanophenyl)methyl]-4-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C=2C=CC(=CC=2)C(=O)NCC=2C=CC(=CC=2)C#N)CC1 PTFCCBDWBUWRTB-UHFFFAOYSA-N 0.000 claims description 2
- LTAMCBAUTUHECW-UHFFFAOYSA-N n-[(4-cyanophenyl)methyl]-4-[[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]amino]benzamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC=3C=CC(=CC=3)C(=O)NCC=3C=CC(=CC=3)C#N)=CC=2)CC1 LTAMCBAUTUHECW-UHFFFAOYSA-N 0.000 claims description 2
- AIJFSOPJUPPZAC-UHFFFAOYSA-N n-[1-(4-cyanobenzoyl)piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC2)C(=O)C=2C=CC(=CC=2)C#N)CC1 AIJFSOPJUPPZAC-UHFFFAOYSA-N 0.000 claims description 2
- MHLHQNWCMLCICH-UHFFFAOYSA-N n-[1-(4-cyanophenyl)piperidin-4-yl]-6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC2)C=2C=CC(=CC=2)C#N)CC1 MHLHQNWCMLCICH-UHFFFAOYSA-N 0.000 claims description 2
- MJVVGQPISJDCKE-UHFFFAOYSA-N n-[1-(4-cyanophenyl)sulfonylpiperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC2)S(=O)(=O)C=2C=CC(=CC=2)C#N)CC1 MJVVGQPISJDCKE-UHFFFAOYSA-N 0.000 claims description 2
- KUYAVZMMGBODBA-UHFFFAOYSA-N n-[1-(cyclohexanecarbonyl)piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC2)C(=O)C2CCCCC2)CC1 KUYAVZMMGBODBA-UHFFFAOYSA-N 0.000 claims description 2
- KCGHFTHUSALUFF-UHFFFAOYSA-N n-[1-(cyclohexylmethyl)piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC3CCCCC3)CC2)CC1 KCGHFTHUSALUFF-UHFFFAOYSA-N 0.000 claims description 2
- ADMHSPDKZAALOS-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[3-(4-fluorophenoxy)pyrrolidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)CC1 ADMHSPDKZAALOS-UHFFFAOYSA-N 0.000 claims description 2
- JTXPMIJNGKYFRZ-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[3-[(4-fluorophenyl)methoxy]azetidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1COC1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)C1 JTXPMIJNGKYFRZ-UHFFFAOYSA-N 0.000 claims description 2
- QPCNUSNHBFCPAM-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-fluorophenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)CC1 QPCNUSNHBFCPAM-UHFFFAOYSA-N 0.000 claims description 2
- HIVGHAUHDXNYQB-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)CC1 HIVGHAUHDXNYQB-UHFFFAOYSA-N 0.000 claims description 2
- JEBWTTQATIZHGU-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)CC1 JEBWTTQATIZHGU-UHFFFAOYSA-N 0.000 claims description 2
- APBUQRJICSRSSS-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound FC1=CC(F)=CC(CN2CCC(CC2)NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C(F)(F)F)=C1 APBUQRJICSRSSS-UHFFFAOYSA-N 0.000 claims description 2
- FKPPDDDQZXPHNG-UHFFFAOYSA-N n-[1-[(3-fluoro-4-methoxyphenyl)methyl]piperidin-4-yl]-6-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(OC)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)CC1 FKPPDDDQZXPHNG-UHFFFAOYSA-N 0.000 claims description 2
- LQGICZMHJVYZGC-UHFFFAOYSA-N n-[1-[(4-cyano-3-fluorophenyl)methyl]piperidin-4-yl]-6-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=C(C#N)C(F)=CC(CN2CCC(CC2)NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)=C1 LQGICZMHJVYZGC-UHFFFAOYSA-N 0.000 claims description 2
- AHTSNSKNLLGNAL-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-(4-pyridin-4-yloxypiperidine-1-carbonyl)pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=CN=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 AHTSNSKNLLGNAL-UHFFFAOYSA-N 0.000 claims description 2
- XJFFGYUNDZFZOG-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-(piperazine-1-carbonyl)pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCNCC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 XJFFGYUNDZFZOG-UHFFFAOYSA-N 0.000 claims description 2
- RLJZRJSNAZYVPY-HHHXNRCGSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[(3r)-3-(4-fluorophenoxy)pyrrolidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1O[C@H]1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 RLJZRJSNAZYVPY-HHHXNRCGSA-N 0.000 claims description 2
- RSHRVHMHGAFLSZ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[3-(3-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound COC1=CC=CC(OC2CN(CCC2)C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)=C1 RSHRVHMHGAFLSZ-UHFFFAOYSA-N 0.000 claims description 2
- RLJZRJSNAZYVPY-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[3-(4-fluorophenoxy)pyrrolidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 RLJZRJSNAZYVPY-UHFFFAOYSA-N 0.000 claims description 2
- KFXYGIMFSTTWQR-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[3-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CCC1 KFXYGIMFSTTWQR-UHFFFAOYSA-N 0.000 claims description 2
- JUPFXDZHGLSJJR-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[3-[(4-fluorophenyl)methoxy]azetidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1COC1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)C1 JUPFXDZHGLSJJR-UHFFFAOYSA-N 0.000 claims description 2
- XRDMDDSSWUSOAX-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 XRDMDDSSWUSOAX-UHFFFAOYSA-N 0.000 claims description 2
- NTZCHZCFSJZAQG-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(2,4-difluorophenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound FC1=CC(F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 NTZCHZCFSJZAQG-UHFFFAOYSA-N 0.000 claims description 2
- RVVFUTBGTJOJLC-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(3,4-difluorobenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 RVVFUTBGTJOJLC-UHFFFAOYSA-N 0.000 claims description 2
- BUTSOOYTBYLGPV-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(3,4-difluorophenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=C(F)C(F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 BUTSOOYTBYLGPV-UHFFFAOYSA-N 0.000 claims description 2
- KAPJCNOKYHCMQW-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-fluorophenyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 KAPJCNOKYHCMQW-UHFFFAOYSA-N 0.000 claims description 2
- HVAFECNXPDQFSX-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxybenzoyl)piperidin-1-yl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 HVAFECNXPDQFSX-UHFFFAOYSA-N 0.000 claims description 2
- PXNMSZNSQODFJQ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[(3,5-difluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound FC1=CC(F)=CC(CN2CCN(CC2)C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)=C1 PXNMSZNSQODFJQ-UHFFFAOYSA-N 0.000 claims description 2
- XGUKVBQSHUARJJ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[(3-fluoro-4-methoxyphenyl)methyl]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=C(F)C(OC)=CC=C1CC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 XGUKVBQSHUARJJ-UHFFFAOYSA-N 0.000 claims description 2
- WNLKAYDTKKISBN-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[(4-fluorophenyl)-hydroxymethyl]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(F)C=CC=1C(O)C(CC1)CCN1C(=O)C(C=N1)=CC=C1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 WNLKAYDTKKISBN-UHFFFAOYSA-N 0.000 claims description 2
- HUYCPHYFJJCRHE-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(dimethylcarbamoyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 HUYCPHYFJJCRHE-UHFFFAOYSA-N 0.000 claims description 2
- JHRNQZYMFIIVGE-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]pyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1CCN(C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 JHRNQZYMFIIVGE-UHFFFAOYSA-N 0.000 claims description 2
- SWFYJWRPKQUXJE-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 SWFYJWRPKQUXJE-UHFFFAOYSA-N 0.000 claims description 2
- ZRFMAUMUQYAFKO-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethyl)phenyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 ZRFMAUMUQYAFKO-UHFFFAOYSA-N 0.000 claims description 2
- LUSWURPIWQNHMX-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethylsulfonyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 LUSWURPIWQNHMX-UHFFFAOYSA-N 0.000 claims description 2
- WQUGCKCCOOBUNT-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-fluoro-4-(4-fluorobenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)C1(F)CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 WQUGCKCCOOBUNT-UHFFFAOYSA-N 0.000 claims description 2
- SXLNCLDXSZOPBZ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[[1-(4-cyanophenyl)piperidin-4-yl]amino]pyridine-2-carboxamide Chemical compound C=1C=C(NC2CCN(CC2)C=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 SXLNCLDXSZOPBZ-UHFFFAOYSA-N 0.000 claims description 2
- WDIUOLAJMWXWDH-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[[1-(4-fluorophenyl)piperidin-4-yl]amino]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1N1CCC(NC=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 WDIUOLAJMWXWDH-UHFFFAOYSA-N 0.000 claims description 2
- KXVNZBABMIWAFP-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[[1-(4-methoxyphenyl)piperidin-4-yl]amino]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1N1CCC(NC=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 KXVNZBABMIWAFP-UHFFFAOYSA-N 0.000 claims description 2
- CZGHJHFJDOKLEU-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 CZGHJHFJDOKLEU-UHFFFAOYSA-N 0.000 claims description 2
- CQZOSLVFDRPCFJ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(2,4-difluorophenoxy)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 CQZOSLVFDRPCFJ-UHFFFAOYSA-N 0.000 claims description 2
- UZPPXFTWQGIEIS-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidin-1-yl]pyridazine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C=2N=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 UZPPXFTWQGIEIS-UHFFFAOYSA-N 0.000 claims description 2
- DSEUJSHMFHEHFZ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-nitrophenoxy)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 DSEUJSHMFHEHFZ-UHFFFAOYSA-N 0.000 claims description 2
- CLJBRWCXTFMREC-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(cyclopropylsulfonylamino)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=CC(NS(=O)(=O)C3CC3)=CC=2)N=CC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 CLJBRWCXTFMREC-UHFFFAOYSA-N 0.000 claims description 2
- GJMRQEGEEYASHD-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(methanesulfonamido)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 GJMRQEGEEYASHD-UHFFFAOYSA-N 0.000 claims description 2
- YTSTYPROPVLXLB-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]pyridazine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1CCN(C=2N=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 YTSTYPROPVLXLB-UHFFFAOYSA-N 0.000 claims description 2
- PKZHINNMONLOBK-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(trifluoromethylsulfanyl)phenoxy]piperidine-1-carbonyl]pyridazine-3-carboxamide Chemical compound C1=CC(SC(F)(F)F)=CC=C1OC1CCN(C(=O)C=2N=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 PKZHINNMONLOBK-UHFFFAOYSA-N 0.000 claims description 2
- XVUVHIMZDREIIH-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(trifluoromethylsulfonyl)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 XVUVHIMZDREIIH-UHFFFAOYSA-N 0.000 claims description 2
- RJDFHCCYYFFSBE-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]pyrazol-3-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2=NN(CC=3C=CC(=CC=3)C#N)C=C2)CC1 RJDFHCCYYFFSBE-UHFFFAOYSA-N 0.000 claims description 2
- NFOUIFJMANKDPS-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]pyrazol-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2=CN(CC=3C=CC(=CC=3)C#N)N=C2)CC1 NFOUIFJMANKDPS-UHFFFAOYSA-N 0.000 claims description 2
- MYKBCPMYGPOKII-UHFFFAOYSA-N n-[1-[(4-fluoro-3-methylphenyl)methyl]piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=C(F)C(C)=CC(CN2CCC(CC2)NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)=C1 MYKBCPMYGPOKII-UHFFFAOYSA-N 0.000 claims description 2
- HUMCBAOVNNNRNA-UHFFFAOYSA-N n-[1-[(4-propan-2-yloxyphenyl)methyl]piperidin-4-yl]-6-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC(C)C)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)CC1 HUMCBAOVNNNRNA-UHFFFAOYSA-N 0.000 claims description 2
- MLGAAABCCVIOEF-UHFFFAOYSA-N n-[2-(4-fluorophenoxy)ethyl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NCCOC=2C=CC(F)=CC=2)CC1 MLGAAABCCVIOEF-UHFFFAOYSA-N 0.000 claims description 2
- WBQCMGADTQIKRW-UHFFFAOYSA-N n-[4-(3,5-difluorophenoxy)cyclohexyl]-5-[4-(4-fluorophenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=C(F)C=C(F)C=2)CC1 WBQCMGADTQIKRW-UHFFFAOYSA-N 0.000 claims description 2
- WUUYOPINRPLTPV-UHFFFAOYSA-N n-[4-(3,5-difluorophenoxy)cyclohexyl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=C(F)C=C(F)C=2)CC1 WUUYOPINRPLTPV-UHFFFAOYSA-N 0.000 claims description 2
- ZGVPWOWZROQALT-UHFFFAOYSA-N n-[4-(3-cyanophenoxy)phenyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(OC=3C=C(C=CC=3)C#N)=CC=2)CC1 ZGVPWOWZROQALT-UHFFFAOYSA-N 0.000 claims description 2
- GVARIDOMGKXGSD-UHFFFAOYSA-N n-[4-(3-cyanophenyl)phenyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C=2C=C(C=CC=2)C#N)CC1 GVARIDOMGKXGSD-UHFFFAOYSA-N 0.000 claims description 2
- AFHGWQBLKGCROK-UHFFFAOYSA-N n-[4-(3-fluorophenoxy)phenyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(OC=3C=C(F)C=CC=3)=CC=2)CC1 AFHGWQBLKGCROK-UHFFFAOYSA-N 0.000 claims description 2
- QXYDKUCICQMFKB-UHFFFAOYSA-N n-[4-(4-cyanophenoxy)cyclohexyl]-6-[4-(4-cyanophenoxy)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)N=CC=1C(=O)NC(CC1)CCC1OC1=CC=C(C#N)C=C1 QXYDKUCICQMFKB-UHFFFAOYSA-N 0.000 claims description 2
- PWNFGRQMNJTNJN-UHFFFAOYSA-N n-[4-(4-cyanophenoxy)cyclohexyl]-6-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)N=CC=1C(=O)NC(CC1)CCC1OC1=CC=C(C#N)C=C1 PWNFGRQMNJTNJN-UHFFFAOYSA-N 0.000 claims description 2
- QMTWAPVKHUNKFZ-UHFFFAOYSA-N n-[4-(4-cyanophenoxy)cyclohexyl]-6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 QMTWAPVKHUNKFZ-UHFFFAOYSA-N 0.000 claims description 2
- JKWVHOJBLXODFV-UHFFFAOYSA-N n-[4-(4-cyanophenoxy)cyclohexyl]-6-[4-[3-(cyclopropanecarbonylamino)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1CC1C(=O)NC(C=1)=CC=CC=1OC(CC1)CCN1C(=O)C(N=C1)=CC=C1C(=O)NC(CC1)CCC1OC1=CC=C(C#N)C=C1 JKWVHOJBLXODFV-UHFFFAOYSA-N 0.000 claims description 2
- RANWOMLEXKWTRY-UHFFFAOYSA-N n-[4-(4-cyanophenoxy)phenyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 RANWOMLEXKWTRY-UHFFFAOYSA-N 0.000 claims description 2
- XSUMTXIVYVXHQF-UHFFFAOYSA-N n-[4-(4-cyanophenyl)phenyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C=2C=CC(=CC=2)C#N)CC1 XSUMTXIVYVXHQF-UHFFFAOYSA-N 0.000 claims description 2
- VGTANERTDXIGKZ-UHFFFAOYSA-N n-[4-(4-fluorophenoxy)cyclohexyl]-5-[4-(4-fluorophenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(F)=CC=2)CC1 VGTANERTDXIGKZ-UHFFFAOYSA-N 0.000 claims description 2
- DDIKEHGCFSSELH-UHFFFAOYSA-N n-[4-(4-fluorophenoxy)cyclohexyl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(F)=CC=2)CC1 DDIKEHGCFSSELH-UHFFFAOYSA-N 0.000 claims description 2
- NOIUJGNQSASNRI-UHFFFAOYSA-N n-[4-(4-fluorophenoxy)phenyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)CC1 NOIUJGNQSASNRI-UHFFFAOYSA-N 0.000 claims description 2
- BPUSTKQLALECFR-UHFFFAOYSA-N n-[4-[(4-cyanophenyl)methylcarbamoyl]phenyl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=CC(=CC=2)C(=O)NCC=2C=CC(=CC=2)C#N)CC1 BPUSTKQLALECFR-UHFFFAOYSA-N 0.000 claims description 2
- ASBBFNPPGCMMTH-UHFFFAOYSA-N n-[6-(3-cyanophenoxy)pyridin-3-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=C(C=CC=3)C#N)=CC=2)CC1 ASBBFNPPGCMMTH-UHFFFAOYSA-N 0.000 claims description 2
- SXCVHBDVDRBZIC-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)pyridin-3-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 SXCVHBDVDRBZIC-UHFFFAOYSA-N 0.000 claims description 2
- XOCNQFFZQFEWHW-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 XOCNQFFZQFEWHW-UHFFFAOYSA-N 0.000 claims description 2
- HOYLOGISDOAXOM-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 HOYLOGISDOAXOM-UHFFFAOYSA-N 0.000 claims description 2
- 230000008816 organ damage Effects 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- GFDOYTAWIKLKSA-UHFFFAOYSA-N 2-n,5-n-bis(1-benzylpiperidin-4-yl)pyridine-2,5-dicarboxamide Chemical compound C=1C=C(C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)N=CC=1C(=O)NC(CC1)CCN1CC1=CC=CC=C1 GFDOYTAWIKLKSA-UHFFFAOYSA-N 0.000 claims 1
- ZNLOQOLMQYQXNI-UHFFFAOYSA-N 2-n,6-n-bis[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2,6-dicarboxamide Chemical compound C=1C=CC(C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 ZNLOQOLMQYQXNI-UHFFFAOYSA-N 0.000 claims 1
- RKTWPHQFWGVWFF-UHFFFAOYSA-N 2-n,6-n-bis[1-[(4-fluorophenyl)methyl]piperidin-4-yl]pyridine-2,6-dicarboxamide Chemical compound C1=CC(F)=CC=C1CN1CCC(NC(=O)C=2N=C(C=CC=2)C(=O)NC2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 RKTWPHQFWGVWFF-UHFFFAOYSA-N 0.000 claims 1
- OWORLXKPKKUEKB-UHFFFAOYSA-N 2-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-n-[1-[(4-cyanophenyl)methyl]pyrazol-3-yl]pyridine-2,5-dicarboxamide Chemical compound C=1C=C(C(=O)NC2=NN(CC=3C=CC(=CC=3)C#N)C=C2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 OWORLXKPKKUEKB-UHFFFAOYSA-N 0.000 claims 1
- YHEKUCFWUXSDKM-UHFFFAOYSA-N 2-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-n-[1-[(4-cyanophenyl)methyl]pyrazol-4-yl]pyridine-2,5-dicarboxamide Chemical compound C=1C=C(C(=O)NC2=CN(CC=3C=CC(=CC=3)C#N)N=C2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 YHEKUCFWUXSDKM-UHFFFAOYSA-N 0.000 claims 1
- PTNAVJCDQOQYQW-BXWFABGCSA-N 4-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-[2-[2-(3-amino-3-oxopropoxy)ethoxy]ethoxy]ethoxy]ethyl]butanamide Chemical compound NC(=O)CCOCCOCCOCCOCCNC(=O)CCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 PTNAVJCDQOQYQW-BXWFABGCSA-N 0.000 claims 1
- HJQDYLZIUZAGJL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]piperazine-1-carbaldehyde Chemical compound C1=CC(F)=CC=C1CN1CCN(C=O)CC1 HJQDYLZIUZAGJL-UHFFFAOYSA-N 0.000 claims 1
- BWGZBBSRFIGRTF-UHFFFAOYSA-N 4-[1-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]piperidin-4-yl]oxybenzonitrile Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 BWGZBBSRFIGRTF-UHFFFAOYSA-N 0.000 claims 1
- UZKLXKCSYXORTD-UHFFFAOYSA-N 5-(4-benzoylpiperazine-1-carbonyl)-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)C(=O)C=2C=CC=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 UZKLXKCSYXORTD-UHFFFAOYSA-N 0.000 claims 1
- ZTXYRALKNNXSHH-UHFFFAOYSA-N 5-(4-benzylanilino)-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(NC=2C=CC(CC=3C=CC=CC=3)=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 ZTXYRALKNNXSHH-UHFFFAOYSA-N 0.000 claims 1
- TUXSVDQMBSARPI-UHFFFAOYSA-N 5-(4-benzylpiperazin-1-yl)-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(N2CCN(CC=3C=CC=CC=3)CC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 TUXSVDQMBSARPI-UHFFFAOYSA-N 0.000 claims 1
- JZOSWLKELUSKPW-SANMLTNESA-N 5-[(3s)-3-(4-fluorophenoxy)pyrrolidine-1-carbonyl]-n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2C[C@H](CC2)OC=2C=CC(F)=CC=2)CC1 JZOSWLKELUSKPW-SANMLTNESA-N 0.000 claims 1
- WKWOWUPNJQOYOV-UHFFFAOYSA-N 5-[3-(4-cyanophenoxy)azetidine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CC(C2)OC=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 WKWOWUPNJQOYOV-UHFFFAOYSA-N 0.000 claims 1
- JGBMPZMXPFSPDG-UHFFFAOYSA-N 5-[3-(4-cyanophenoxy)azetidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CC(C2)OC=2C=CC(=CC=2)C#N)C=N1 JGBMPZMXPFSPDG-UHFFFAOYSA-N 0.000 claims 1
- WJFHULPMCHGBBX-UHFFFAOYSA-N 5-[3-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CC(CCC2)OC=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 WJFHULPMCHGBBX-UHFFFAOYSA-N 0.000 claims 1
- NFXJMTPKKPWDFD-UHFFFAOYSA-N 5-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyrazine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CN=C(C(=O)N2CCC(CC2)C(=O)C=2C(=CC(F)=CC=2)F)C=N1 NFXJMTPKKPWDFD-UHFFFAOYSA-N 0.000 claims 1
- QGQJHZASQZDJMZ-UHFFFAOYSA-N 5-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C(=CC(F)=CC=2)F)C=N1 QGQJHZASQZDJMZ-UHFFFAOYSA-N 0.000 claims 1
- RNONESCEJJROHR-UHFFFAOYSA-N 5-[4-(3,4-difluorobenzoyl)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C=C(F)C(F)=CC=2)C=N1 RNONESCEJJROHR-UHFFFAOYSA-N 0.000 claims 1
- CZJQSTWTDOMTMC-UHFFFAOYSA-N 5-[4-(4-acetamidophenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 CZJQSTWTDOMTMC-UHFFFAOYSA-N 0.000 claims 1
- UGQQVZAGWFGYST-UHFFFAOYSA-N 5-[4-(4-acetylphenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 UGQQVZAGWFGYST-UHFFFAOYSA-N 0.000 claims 1
- IJCLQUTZPNXGSE-UHFFFAOYSA-N 5-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-N-[4-[4-(trifluoromethyl)phenoxy]cyclohexyl]pyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 IJCLQUTZPNXGSE-UHFFFAOYSA-N 0.000 claims 1
- BPMMMRKHRUQAAY-UHFFFAOYSA-N 5-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 BPMMMRKHRUQAAY-UHFFFAOYSA-N 0.000 claims 1
- JLWLTWZTDHMFKR-UHFFFAOYSA-N 5-[4-(4-fluorobenzoyl)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(F)=CC=2)C=N1 JLWLTWZTDHMFKR-UHFFFAOYSA-N 0.000 claims 1
- YUSQDVWUKSSAEC-UHFFFAOYSA-N 5-[4-(4-fluorophenoxy)piperidine-1-carbonyl]-n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(F)=CC=2)CC1 YUSQDVWUKSSAEC-UHFFFAOYSA-N 0.000 claims 1
- CIXKEBBNLUBQNZ-UHFFFAOYSA-N 5-[4-(4-fluorophenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 CIXKEBBNLUBQNZ-UHFFFAOYSA-N 0.000 claims 1
- QJSNZYYRFPKWGV-UHFFFAOYSA-N 5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]-N-[4-(4-methoxyphenoxy)phenyl]pyridine-2-carboxamide Chemical compound COc1ccc(Oc2ccc(NC(=O)c3ccc(cn3)C(=O)N3CCC(CC3)C(=O)c3ccc(OC)cc3)cc2)cc1 QJSNZYYRFPKWGV-UHFFFAOYSA-N 0.000 claims 1
- SWQOOGAKPQTEBM-UHFFFAOYSA-N 5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]-N-[4-[4-(trifluoromethyl)phenoxy]cyclohexyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C(F)(F)F)CC1 SWQOOGAKPQTEBM-UHFFFAOYSA-N 0.000 claims 1
- SHXRZVBBZQBCEM-UHFFFAOYSA-N 5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]-N-[4-[4-(trifluoromethyl)phenoxy]cyclohexyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C(F)(F)F)CC1 SHXRZVBBZQBCEM-UHFFFAOYSA-N 0.000 claims 1
- GAPLEWRIBFUXRK-UHFFFAOYSA-N 5-[4-(4-methylsulfonylphenoxy)piperidine-1-carbonyl]-n-[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(OC(F)(F)F)C=CC=3)CC2)CC1 GAPLEWRIBFUXRK-UHFFFAOYSA-N 0.000 claims 1
- UFEIEYBIRIUWRQ-UHFFFAOYSA-N 5-[4-(benzenesulfonyl)piperazine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 UFEIEYBIRIUWRQ-UHFFFAOYSA-N 0.000 claims 1
- HQTGOKGRHCNFPD-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-(1-phenylpiperidin-4-yl)pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC2)C=2C=CC=CC=2)CC1 HQTGOKGRHCNFPD-UHFFFAOYSA-N 0.000 claims 1
- KMRPXMWIZLSCAG-IZZNHLLZSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[(3s,4r)-3-fluoro-1-(pyridin-4-ylmethyl)piperidin-4-yl]pyridine-2-carboxamide Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)F)N1CC1=CC=NC=C1 KMRPXMWIZLSCAG-IZZNHLLZSA-N 0.000 claims 1
- SSXKELDQHCLBAC-VQTJNVASSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[(3s,4r)-3-fluoropiperidin-4-yl]pyridine-2-carboxamide Chemical compound F[C@H]1CNCC[C@H]1NC(=O)C1=CC=C(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)C=N1 SSXKELDQHCLBAC-VQTJNVASSA-N 0.000 claims 1
- OTTMHRBJZANTRA-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[1-(1-phenylethyl)piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=CC=CC=1C(C)N(CC1)CCC1NC(=O)C(N=C1)=CC=C1C(=O)N(CC1)CCN1CC1=CC=C(F)C=C1 OTTMHRBJZANTRA-UHFFFAOYSA-N 0.000 claims 1
- JBOAVLPHPAENSA-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 JBOAVLPHPAENSA-UHFFFAOYSA-N 0.000 claims 1
- BBMMNIYHXIHSPL-UHFFFAOYSA-N 5-[4-[4-(dimethylcarbamoyl)phenoxy]piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 BBMMNIYHXIHSPL-UHFFFAOYSA-N 0.000 claims 1
- AUDCQJXZPQEOHW-UHFFFAOYSA-N 5-[[1-(4-chlorophenyl)piperidin-4-yl]amino]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1CCC(NC=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 AUDCQJXZPQEOHW-UHFFFAOYSA-N 0.000 claims 1
- PJEQHYITGSHAGC-UHFFFAOYSA-N 5-n-(3-benzylphenyl)-2-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2,5-dicarboxamide Chemical compound C=1C=C(C(=O)NC=2C=C(CC=3C=CC=CC=3)C=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 PJEQHYITGSHAGC-UHFFFAOYSA-N 0.000 claims 1
- YJVUDJAYUHJDRZ-UHFFFAOYSA-N 6-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]-n-[6-(4-methylsulfonylphenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C(=CC(F)=CC=2)F)N=C1 YJVUDJAYUHJDRZ-UHFFFAOYSA-N 0.000 claims 1
- CSMZDTSEHGVTML-UHFFFAOYSA-N 6-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]-n-[6-[4-(dimethylcarbamoyl)phenoxy]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C(=CC(F)=CC=2)F)N=C1 CSMZDTSEHGVTML-UHFFFAOYSA-N 0.000 claims 1
- GUJSBGWSDRFUAC-UHFFFAOYSA-N 6-[4-(2,4-difluorophenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)OC=2C(=CC(F)=CC=2)F)N=C1 GUJSBGWSDRFUAC-UHFFFAOYSA-N 0.000 claims 1
- NXUARYUTSSUSSG-UHFFFAOYSA-N 6-[4-(4-acetamidophenoxy)piperidine-1-carbonyl]-n-[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=C(OC(F)(F)F)C=CC=3)CC2)CC1 NXUARYUTSSUSSG-UHFFFAOYSA-N 0.000 claims 1
- ACJLYGUYLHGBRM-UHFFFAOYSA-N 6-[4-(4-acetylphenoxy)piperidine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridazine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC1CCN(C(=O)C=2N=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 ACJLYGUYLHGBRM-UHFFFAOYSA-N 0.000 claims 1
- RKZZIRZVMZFRAJ-UHFFFAOYSA-N 6-[4-(4-acetylphenoxy)piperidine-1-carbonyl]-n-[4-(4-cyanophenoxy)cyclohexyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 RKZZIRZVMZFRAJ-UHFFFAOYSA-N 0.000 claims 1
- PCKCBYIEMJBCQJ-UHFFFAOYSA-N 6-[4-(4-acetylphenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 PCKCBYIEMJBCQJ-UHFFFAOYSA-N 0.000 claims 1
- BZJYUHBEBJBKFU-UHFFFAOYSA-N 6-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridazine-3-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)N=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 BZJYUHBEBJBKFU-UHFFFAOYSA-N 0.000 claims 1
- KHXARCSTRQBUHC-UHFFFAOYSA-N 6-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[1-[[4-(methanesulfonamido)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 KHXARCSTRQBUHC-UHFFFAOYSA-N 0.000 claims 1
- DSZCBNUFKPZERX-UHFFFAOYSA-N 6-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 DSZCBNUFKPZERX-UHFFFAOYSA-N 0.000 claims 1
- XSUNUTFPDUBUTM-UHFFFAOYSA-N 6-[4-(4-cyanophenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C#N)N=C1 XSUNUTFPDUBUTM-UHFFFAOYSA-N 0.000 claims 1
- LOCVLBUUUHGTAV-UHFFFAOYSA-N 6-[4-(4-cyclopropylsulfonylphenoxy)piperidine-1-carbonyl]-n-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(=O)(=O)C2CC2)CC1 LOCVLBUUUHGTAV-UHFFFAOYSA-N 0.000 claims 1
- ZZWJDICOSBHOKT-UHFFFAOYSA-N 6-[4-(4-cyclopropylsulfonylphenoxy)piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(=O)(=O)C2CC2)N=C1 ZZWJDICOSBHOKT-UHFFFAOYSA-N 0.000 claims 1
- KCEAIMNCDQJEOH-UHFFFAOYSA-N 6-[4-(4-fluorophenyl)sulfonylpiperidine-1-carbonyl]-n-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(OC(F)(F)F)=CC=3)CC2)CC1 KCEAIMNCDQJEOH-UHFFFAOYSA-N 0.000 claims 1
- HHOJNLQASSTSAG-UHFFFAOYSA-N 6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]-n-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-n-methylpyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(N(C)C(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)C(=O)C=2C=CC(OC)=CC=2)CC1 HHOJNLQASSTSAG-UHFFFAOYSA-N 0.000 claims 1
- WWMWPFIHGSDSJL-UHFFFAOYSA-N 6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]-n-[6-(4-methylsulfonylphenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)S(C)(=O)=O)=CC=2)CC1 WWMWPFIHGSDSJL-UHFFFAOYSA-N 0.000 claims 1
- HLFMHUFIGPKBDK-UHFFFAOYSA-N 6-[4-(4-methylsulfonylphenoxy)piperidine-1-carbonyl]-n-[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=C(OC(F)(F)F)C=CC=3)CC2)CC1 HLFMHUFIGPKBDK-UHFFFAOYSA-N 0.000 claims 1
- VGOONDYBJSKCBN-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[1-(4-fluorophenyl)piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC2)C=2C=CC(F)=CC=2)CC1 VGOONDYBJSKCBN-UHFFFAOYSA-N 0.000 claims 1
- FKSSSDMQVIYXCQ-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[1-(4-methoxyphenyl)piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1N1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 FKSSSDMQVIYXCQ-UHFFFAOYSA-N 0.000 claims 1
- JKAJRLZIQKBLFQ-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 JKAJRLZIQKBLFQ-UHFFFAOYSA-N 0.000 claims 1
- ZEJJGUPFZSMWAX-UHFFFAOYSA-N 6-[4-[3-(cyclopropanecarbonylamino)phenoxy]piperidine-1-carbonyl]-n-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=C(NC(=O)C3CC3)C=CC=2)CC1 ZEJJGUPFZSMWAX-UHFFFAOYSA-N 0.000 claims 1
- VUYRMWJLJSPEAR-UHFFFAOYSA-N 6-[4-[4-(cyclopropanecarbonyl)phenoxy]piperidine-1-carbonyl]-n-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C(=O)C2CC2)CC1 VUYRMWJLJSPEAR-UHFFFAOYSA-N 0.000 claims 1
- WYUCTYJNLHAUHO-UHFFFAOYSA-N 6-[4-[4-(cyclopropylsulfonylamino)phenoxy]piperidine-1-carbonyl]-n-[6-(4-fluorophenoxy)pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)OC=2C=CC(NS(=O)(=O)C3CC3)=CC=2)N=C1 WYUCTYJNLHAUHO-UHFFFAOYSA-N 0.000 claims 1
- IRXMWPNSDLENHP-UHFFFAOYSA-N 6-[4-[4-(pentafluoro-$l^{6}-sulfanyl)phenoxy]piperidine-1-carbonyl]-n-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]pyridine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(F)(F)(F)(F)F)CC1 IRXMWPNSDLENHP-UHFFFAOYSA-N 0.000 claims 1
- YSAKXSLSNHUKPX-UHFFFAOYSA-N C(C1=CN=CC=C1)(=O)NC1CCN(CC1)CC1=CC=C(C=C1)N1CCCC1 Chemical compound C(C1=CN=CC=C1)(=O)NC1CCN(CC1)CC1=CC=C(C=C1)N1CCCC1 YSAKXSLSNHUKPX-UHFFFAOYSA-N 0.000 claims 1
- KGDGVGWNVIEHQL-UHFFFAOYSA-N C1C(NC(=O)C2=CC=C(C(=O)N3CCC(C(=O)C4=CC=C(C)C=C4)CC3)N=C2)CCN(C1)CC1=CC=C(C#N)C=C1 Chemical compound C1C(NC(=O)C2=CC=C(C(=O)N3CCC(C(=O)C4=CC=C(C)C=C4)CC3)N=C2)CCN(C1)CC1=CC=C(C#N)C=C1 KGDGVGWNVIEHQL-UHFFFAOYSA-N 0.000 claims 1
- KHKOALZGRAJSFA-UHFFFAOYSA-N CC(C)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CC(C)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N KHKOALZGRAJSFA-UHFFFAOYSA-N 0.000 claims 1
- ATXVRIMQWFAQOK-UHFFFAOYSA-N CC(C)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C Chemical compound CC(C)C1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C ATXVRIMQWFAQOK-UHFFFAOYSA-N 0.000 claims 1
- JHTZDDUIDJQPJL-UHFFFAOYSA-N CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N JHTZDDUIDJQPJL-UHFFFAOYSA-N 0.000 claims 1
- WSHUFJLKIMPHGV-FQLXRVMXSA-N CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)N[C@@H]4CCN(C[C@H]4F)CC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)N[C@@H]4CCN(C[C@H]4F)CC5=CC=C(C=C5)C#N WSHUFJLKIMPHGV-FQLXRVMXSA-N 0.000 claims 1
- IMOHABWBRHBSLW-UHFFFAOYSA-N CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)F Chemical compound CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)F IMOHABWBRHBSLW-UHFFFAOYSA-N 0.000 claims 1
- ULVQTPRAEGEBBG-UHFFFAOYSA-N CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)F Chemical compound CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)F ULVQTPRAEGEBBG-UHFFFAOYSA-N 0.000 claims 1
- NDAAPEZTNBMFSX-UHFFFAOYSA-N CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)OC Chemical compound CC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)OC NDAAPEZTNBMFSX-UHFFFAOYSA-N 0.000 claims 1
- NIJAFYOANGVJPO-UHFFFAOYSA-N CC1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N NIJAFYOANGVJPO-UHFFFAOYSA-N 0.000 claims 1
- YDHXJIHQYNMLIF-UHFFFAOYSA-N CC1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C Chemical compound CC1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C YDHXJIHQYNMLIF-UHFFFAOYSA-N 0.000 claims 1
- PJSJDTHVWVECNP-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C PJSJDTHVWVECNP-UHFFFAOYSA-N 0.000 claims 1
- HRXDQFIBPTVVSO-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4=CN=C(C=C4)S(=O)(=O)C5=CC=C(C=C5)F Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4=CN=C(C=C4)S(=O)(=O)C5=CC=C(C=C5)F HRXDQFIBPTVVSO-UHFFFAOYSA-N 0.000 claims 1
- LKRAGLNUAHXJNT-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC(=CC=C5)OC Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC(=CC=C5)OC LKRAGLNUAHXJNT-UHFFFAOYSA-N 0.000 claims 1
- FRTBKUDRDRDNQH-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N FRTBKUDRDRDNQH-UHFFFAOYSA-N 0.000 claims 1
- ODBQSZFTJYTYMN-FQLXRVMXSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)N[C@@H]4CCN(C[C@H]4F)CC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)N[C@@H]4CCN(C[C@H]4F)CC5=CC=C(C=C5)C#N ODBQSZFTJYTYMN-FQLXRVMXSA-N 0.000 claims 1
- HFCRTCMPAUPEJW-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)CC5=CC=C(C=C5)F Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)CC5=CC=C(C=C5)F HFCRTCMPAUPEJW-UHFFFAOYSA-N 0.000 claims 1
- PAIRWBQYWPIOKM-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4=CN=C(C=C4)OC5=CC=C(C=C5)C(=O)C PAIRWBQYWPIOKM-UHFFFAOYSA-N 0.000 claims 1
- WKVDROGTYQLCHC-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCC(CC4)OC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCC(CC4)OC5=CC=C(C=C5)C#N WKVDROGTYQLCHC-UHFFFAOYSA-N 0.000 claims 1
- XELPDCRJZXPXEC-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC(=CC(=C5)F)F Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC(=CC(=C5)F)F XELPDCRJZXPXEC-UHFFFAOYSA-N 0.000 claims 1
- SUIBOECFXUWNJD-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC(=CC=C5)OC Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC(=CC=C5)OC SUIBOECFXUWNJD-UHFFFAOYSA-N 0.000 claims 1
- PQDNQTAVIFKNLY-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N PQDNQTAVIFKNLY-UHFFFAOYSA-N 0.000 claims 1
- UUZOPWSYPZJFBK-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)F Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)F UUZOPWSYPZJFBK-UHFFFAOYSA-N 0.000 claims 1
- GNPZRGSPKYRVQL-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)OC Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)OC GNPZRGSPKYRVQL-UHFFFAOYSA-N 0.000 claims 1
- RFYYTEWAEFWDKF-UHFFFAOYSA-N CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CC1=CC=C(C=C1)OC2CCN(CC2)C(=O)C3=NN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N RFYYTEWAEFWDKF-UHFFFAOYSA-N 0.000 claims 1
- HHGYWGZUFUZIJY-UHFFFAOYSA-N CCC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CCC1=CC=C(C=C1)C(=O)C2CCN(CC2)C(=O)C3=CN=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N HHGYWGZUFUZIJY-UHFFFAOYSA-N 0.000 claims 1
- OLOZIBNMGBLLJM-UHFFFAOYSA-N CNC1=C(C=CC(=C1)OC)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N Chemical compound CNC1=C(C=CC(=C1)OC)OC2CCN(CC2)C(=O)C3=NC=C(C=C3)C(=O)NC4CCN(CC4)CC5=CC=C(C=C5)C#N OLOZIBNMGBLLJM-UHFFFAOYSA-N 0.000 claims 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical group [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- CKXPBSUKGATDRJ-SANMLTNESA-N N-[(3S)-1-[(4-cyanophenyl)methyl]pyrrolidin-3-yl]-5-[4-[(4-fluorophenyl)methyl]-3-oxopiperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound Fc1ccc(CN2CCN(CC2=O)C(=O)c2ccc(nc2)C(=O)N[C@H]2CCN(Cc3ccc(cc3)C#N)C2)cc1 CKXPBSUKGATDRJ-SANMLTNESA-N 0.000 claims 1
- HWOSDYNCBXZMQP-WUFINQPMSA-N N-[(3S,4R)-3-fluoro-1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@H](CN(CC=3C=CC(OC(F)(F)F)=CC=3)CC2)F)CC1 HWOSDYNCBXZMQP-WUFINQPMSA-N 0.000 claims 1
- AJYLLLGCOILHRH-UHFFFAOYSA-N N-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(dimethylamino)benzoyl]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound CN(C)c1ccc(cc1)C(=O)C1CCN(CC1)C(=O)c1ccc(cn1)C(=O)NC1CCN(Cc2ccc(cc2)C#N)CC1 AJYLLLGCOILHRH-UHFFFAOYSA-N 0.000 claims 1
- ILMFTSMWOSIQRL-UHFFFAOYSA-N N-[4-(4-cyano-3-fluorophenoxy)cyclohexyl]-5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound COc1ccc(OC2CCN(CC2)C(=O)c2ccc(nc2)C(=O)NC2CCC(CC2)Oc2ccc(C#N)c(F)c2)cc1 ILMFTSMWOSIQRL-UHFFFAOYSA-N 0.000 claims 1
- FWSGCPSSGXJESZ-UHFFFAOYSA-N N-[4-(4-cyano-3-fluorophenoxy)cyclohexyl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=C(C#N)C(F)=CC(OC2CCC(CC2)NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C(F)(F)F)=C1 FWSGCPSSGXJESZ-UHFFFAOYSA-N 0.000 claims 1
- DXFJCXIKMLXEJV-UHFFFAOYSA-N N-[4-(4-cyanophenoxy)cyclohexyl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 DXFJCXIKMLXEJV-UHFFFAOYSA-N 0.000 claims 1
- QVGHVUBOGYEDKB-UHFFFAOYSA-N N-[4-(4-cyanophenoxy)cyclohexyl]-5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 QVGHVUBOGYEDKB-UHFFFAOYSA-N 0.000 claims 1
- QMWAQWPUELAOOP-UHFFFAOYSA-N N-[4-(4-cyanophenoxy)cyclohexyl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 QMWAQWPUELAOOP-UHFFFAOYSA-N 0.000 claims 1
- KNSGWXFUNINQIP-UHFFFAOYSA-N N-[4-(4-methoxyphenoxy)cyclohexyl]-5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(OC)=CC=2)CC1 KNSGWXFUNINQIP-UHFFFAOYSA-N 0.000 claims 1
- QKTLBWHRMYOPPU-UHFFFAOYSA-N N-[4-(4-methoxyphenoxy)cyclohexyl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C(F)(F)F)CC1 QKTLBWHRMYOPPU-UHFFFAOYSA-N 0.000 claims 1
- CHWFYLUDMGYJQK-UHFFFAOYSA-N [1-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]piperidin-4-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 CHWFYLUDMGYJQK-UHFFFAOYSA-N 0.000 claims 1
- UKCFFODPBLWFIW-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-[4-(2-phenylethyl)piperazine-1-carbonyl]pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)N2CCN(CCC=3C=CC=CC=3)CC2)CC1 UKCFFODPBLWFIW-UHFFFAOYSA-N 0.000 claims 1
- NLRIVKKELMUADS-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)N2CCC(CC2)OC=2C=CC(=CC=2)C(F)(F)F)CC1 NLRIVKKELMUADS-UHFFFAOYSA-N 0.000 claims 1
- HLMPLICAEPSBJM-UHFFFAOYSA-N [6-(4-benzylpiperazine-1-carbonyl)pyridin-3-yl]-(4-benzylpiperazin-1-yl)methanone Chemical compound C=1C=C(C(=O)N2CCN(CC=3C=CC=CC=3)CC2)N=CC=1C(=O)N(CC1)CCN1CC1=CC=CC=C1 HLMPLICAEPSBJM-UHFFFAOYSA-N 0.000 claims 1
- DILDXNXKQQSZDE-UHFFFAOYSA-N [6-[4-(2-phenylethyl)piperazine-1-carbonyl]pyridin-3-yl]-(4-phenylpiperazin-1-yl)methanone Chemical compound C=1C=C(C(=O)N2CCN(CCC=3C=CC=CC=3)CC2)N=CC=1C(=O)N(CC1)CCN1C1=CC=CC=C1 DILDXNXKQQSZDE-UHFFFAOYSA-N 0.000 claims 1
- WELVWANXLGVWPI-UHFFFAOYSA-N [6-[4-(2-phenylethyl)piperazine-1-carbonyl]pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=C(C(=O)N2CCN(CCC=3C=CC=CC=3)CC2)N=C1 WELVWANXLGVWPI-UHFFFAOYSA-N 0.000 claims 1
- XIBAGROKRXXCJI-UHFFFAOYSA-N [6-[4-(2-phenylethyl)piperazine-1-carbonyl]pyridin-3-yl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound C=1C=C(C(=O)N2CCN(CCC=3C=CC=CC=3)CC2)N=CC=1C(=O)N(CC1)CCN1CCC1=CC=CC=C1 XIBAGROKRXXCJI-UHFFFAOYSA-N 0.000 claims 1
- KXOMWEWZJKBODO-UHFFFAOYSA-N [6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]-[4-(2-phenylethyl)piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=C(C=CC=2)C(=O)N2CCN(CCC=3C=CC=CC=3)CC2)CC1 KXOMWEWZJKBODO-UHFFFAOYSA-N 0.000 claims 1
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000018191 liver inflammation Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- SIUGKYLYXCIBJK-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-5-(3-phenoxyanilino)pyridine-2-carboxamide Chemical compound C=1C=C(NC=2C=C(OC=3C=CC=CC=3)C=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=CC=C1 SIUGKYLYXCIBJK-UHFFFAOYSA-N 0.000 claims 1
- ALWPRGJHZOZRBU-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-5-(3-phenylanilino)pyridine-2-carboxamide Chemical compound C=1C=C(NC=2C=C(C=CC=2)C=2C=CC=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=CC=C1 ALWPRGJHZOZRBU-UHFFFAOYSA-N 0.000 claims 1
- DBXTZCORMIZYNR-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-5-(4-phenoxyanilino)pyridine-2-carboxamide Chemical compound C=1C=C(NC=2C=CC(OC=3C=CC=CC=3)=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=CC=C1 DBXTZCORMIZYNR-UHFFFAOYSA-N 0.000 claims 1
- UHYHAUUNDGYPEZ-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-5-(4-phenylpiperazine-1-carbonyl)pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)C=2C=CC=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=CC=C1 UHYHAUUNDGYPEZ-UHFFFAOYSA-N 0.000 claims 1
- LZSZSQKOWNJKPK-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-5-(4-pyridin-4-ylpiperazine-1-carbonyl)pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)C=2C=CN=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=CC=C1 LZSZSQKOWNJKPK-UHFFFAOYSA-N 0.000 claims 1
- GWJLUAVBJOJUAI-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-5-[4-[(5-methyl-1,2-oxazol-3-yl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound O1C(C)=CC(CN2CCN(CC2)C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)=N1 GWJLUAVBJOJUAI-UHFFFAOYSA-N 0.000 claims 1
- ZTMNZDLYLCMZAQ-HHHXNRCGSA-N n-[(3r)-1-[(4-cyanophenyl)methyl]pyrrolidin-3-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)N[C@H]2CN(CC=3C=CC(=CC=3)C#N)CC2)CC1 ZTMNZDLYLCMZAQ-HHHXNRCGSA-N 0.000 claims 1
- BFKLKEDGPVUXEU-VSGBNLITSA-N n-[(3r,4r)-1-[(4-cyanophenyl)methyl]-3-fluoropiperidin-4-yl]-6-[4-[4-(trifluoromethylsulfonyl)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C([C@H]([C@@H](CC1)NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)F)N1CC1=CC=C(C#N)C=C1 BFKLKEDGPVUXEU-VSGBNLITSA-N 0.000 claims 1
- MWVAIOSVWVODAN-VSGBNLITSA-N n-[(3r,4r)-3-fluoro-1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-5-[4-(4-methylsulfonylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)N[C@H]2[C@@H](CN(CC=3C=CC(OC(F)(F)F)=CC=3)CC2)F)CC1 MWVAIOSVWVODAN-VSGBNLITSA-N 0.000 claims 1
- QYKFEEHGZRXLOV-VSGBNLITSA-N n-[(3r,4r)-3-fluoro-1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-5-[4-(4-methylsulfonylphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)N[C@H]2[C@@H](CN(CC=3C=CC(OC(F)(F)F)=CC=3)CC2)F)CC1 QYKFEEHGZRXLOV-VSGBNLITSA-N 0.000 claims 1
- QFCGCJFUXOLOOW-RRPNLBNLSA-N n-[(3s,4r)-1-[(4-chlorophenyl)methyl]-3-fluoropiperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)F)N1CC1=CC=C(Cl)C=C1 QFCGCJFUXOLOOW-RRPNLBNLSA-N 0.000 claims 1
- GGMOGBNZFSCMDK-WUFINQPMSA-N n-[(3s,4r)-1-[(4-cyanophenyl)methyl]-3-fluoropiperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)F)N1CC1=CC=C(C#N)C=C1 GGMOGBNZFSCMDK-WUFINQPMSA-N 0.000 claims 1
- LEUSDRGCPVXECX-VMPREFPWSA-N n-[(3s,4s)-1-[(4-cyanophenyl)methyl]-3-fluoropiperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@@H]2[C@H](CN(CC=3C=CC(=CC=3)C#N)CC2)F)CC1 LEUSDRGCPVXECX-VMPREFPWSA-N 0.000 claims 1
- RAFLQQGXFCLPCT-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-fluorobenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)CC1 RAFLQQGXFCLPCT-UHFFFAOYSA-N 0.000 claims 1
- PQSYSUQLVSDROG-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)CC1 PQSYSUQLVSDROG-UHFFFAOYSA-N 0.000 claims 1
- ZKEBDQJMFGPWQM-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-methylsulfonylphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=C(F)C=C(F)C=3)CC2)CC1 ZKEBDQJMFGPWQM-UHFFFAOYSA-N 0.000 claims 1
- KAGDFRKVOFDGOY-UHFFFAOYSA-N n-[1-[(4-carbamoylphenyl)methyl]piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)N)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 KAGDFRKVOFDGOY-UHFFFAOYSA-N 0.000 claims 1
- GLKJXMSLKUEYGJ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]-3,3-difluoropiperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2C(CN(CC=3C=CC(=CC=3)C#N)CC2)(F)F)CC1 GLKJXMSLKUEYGJ-UHFFFAOYSA-N 0.000 claims 1
- XECSTZQZWRCGSO-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-(4-phenylanilino)pyridine-2-carboxamide Chemical compound C=1C=C(NC=2C=CC(=CC=2)C=2C=CC=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 XECSTZQZWRCGSO-UHFFFAOYSA-N 0.000 claims 1
- SXPSAQUONWUCPN-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-(4-propan-2-ylpiperazine-1-carbonyl)pyridine-2-carboxamide Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=C(C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)N=C1 SXPSAQUONWUCPN-UHFFFAOYSA-N 0.000 claims 1
- CQIGWVFBNAADFU-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[(1-phenylpiperidin-4-yl)amino]pyridine-2-carboxamide Chemical compound C=1C=C(NC2CCN(CC2)C=2C=CC=CC=2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 CQIGWVFBNAADFU-UHFFFAOYSA-N 0.000 claims 1
- BYANCVXDXHRQLT-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(2,2-dimethylpropanoyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C(=O)C1=CC=C(C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)N=C1 BYANCVXDXHRQLT-UHFFFAOYSA-N 0.000 claims 1
- ANTKASWXMLJFBB-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(2-phenylpropan-2-yl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=CC=CC=1C(C)(C)N(CC1)CCN1C(=O)C(C=N1)=CC=C1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 ANTKASWXMLJFBB-UHFFFAOYSA-N 0.000 claims 1
- CWUZNYCHXNYQDR-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-cyclopropylsulfonylphenyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)C=2C=CC(=CC=2)S(=O)(=O)C2CC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 CWUZNYCHXNYQDR-UHFFFAOYSA-N 0.000 claims 1
- RXZOTKZCZZFCCH-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 RXZOTKZCZZFCCH-UHFFFAOYSA-N 0.000 claims 1
- MDZHPVWRGQFKCQ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-fluorophenyl)sulfonylpiperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 MDZHPVWRGQFKCQ-UHFFFAOYSA-N 0.000 claims 1
- LXDHLOOAVAFEJF-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxybenzoyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 LXDHLOOAVAFEJF-UHFFFAOYSA-N 0.000 claims 1
- NPKHHIRWHYYJGW-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyrazine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=NC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 NPKHHIRWHYYJGW-UHFFFAOYSA-N 0.000 claims 1
- AVWVDLCYEHDFRA-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxyphenyl)sulfonylpiperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 AVWVDLCYEHDFRA-UHFFFAOYSA-N 0.000 claims 1
- HQFKPRNNDOUANQ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-methylphenoxy)piperidine-1-carbonyl]pyrazine-2-carboxamide Chemical compound C1=CC(C)=CC=C1OC1CCN(C(=O)C=2N=CC(=NC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 HQFKPRNNDOUANQ-UHFFFAOYSA-N 0.000 claims 1
- FCLDRVKLOOYCDQ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-methylsulfanylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(SC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 FCLDRVKLOOYCDQ-UHFFFAOYSA-N 0.000 claims 1
- WCBBIBOXLBNHOV-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-morpholin-4-ylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCOCC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 WCBBIBOXLBNHOV-UHFFFAOYSA-N 0.000 claims 1
- HVWHBZWYBCRQOP-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyrazine-2-carboxamide Chemical compound C=1N=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 HVWHBZWYBCRQOP-UHFFFAOYSA-N 0.000 claims 1
- WFWVYMHDWSBWSD-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(cyclohexanecarbonyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)C(=O)C2CCCCC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 WFWVYMHDWSBWSD-UHFFFAOYSA-N 0.000 claims 1
- YJICAVIHOWJTJS-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(cyclohexylmethyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC3CCCCC3)CC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 YJICAVIHOWJTJS-UHFFFAOYSA-N 0.000 claims 1
- NMCSHUMJBBZUEI-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(oxan-4-yl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)C2CCOCC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 NMCSHUMJBBZUEI-UHFFFAOYSA-N 0.000 claims 1
- RMUCYZDCFKRSNY-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(pyridin-4-ylmethyl)piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC=3C=CN=CC=3)CC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 RMUCYZDCFKRSNY-UHFFFAOYSA-N 0.000 claims 1
- CCVJKVSSPUWIOG-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]-3,3-dimethylpiperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound CC1(C)CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CCN1CC1=CC=C(F)C=C1 CCVJKVSSPUWIOG-UHFFFAOYSA-N 0.000 claims 1
- WPSUUXHDAQDYPG-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[(4-methoxyphenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 WPSUUXHDAQDYPG-UHFFFAOYSA-N 0.000 claims 1
- RGJWOFQNRMIXJW-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(2,2,2-trifluoroacetyl)phenyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C(=O)C(F)(F)F)=CC=C1N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 RGJWOFQNRMIXJW-UHFFFAOYSA-N 0.000 claims 1
- YFJQTHWORCUTFF-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(4-methylpiperazin-1-yl)benzoyl]piperidine-1-carbonyl]pyrazine-2-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)C2CCN(CC2)C(=O)C=2N=CC(=NC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)C=C1 YFJQTHWORCUTFF-UHFFFAOYSA-N 0.000 claims 1
- CQUHOAICBBXVEG-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(4-methylpiperazin-1-yl)benzoyl]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)C2CCN(CC2)C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)C=C1 CQUHOAICBBXVEG-UHFFFAOYSA-N 0.000 claims 1
- SRJYEJPJELERDT-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(cyclopropanecarbonyl)phenyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC2)C=2C=CC(=CC=2)C(=O)C2CC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 SRJYEJPJELERDT-UHFFFAOYSA-N 0.000 claims 1
- BAQNKGBJRYOBKF-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(pentafluoro-$l^{6}-sulfanyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(S(F)(F)(F)(F)F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 BAQNKGBJRYOBKF-UHFFFAOYSA-N 0.000 claims 1
- AFFMBBJVFRZUEW-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]pyrazine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1CCN(C(=O)C=2N=CC(=NC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 AFFMBBJVFRZUEW-UHFFFAOYSA-N 0.000 claims 1
- CUGRGOQWDRJFLR-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethylsulfanyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(SC(F)(F)F)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 CUGRGOQWDRJFLR-UHFFFAOYSA-N 0.000 claims 1
- CIYOQUUILYLVDA-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethylsulfonyl)phenyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1N1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 CIYOQUUILYLVDA-UHFFFAOYSA-N 0.000 claims 1
- FJNHSBVZTQFKEF-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[fluoro-(4-fluorophenyl)methyl]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(F)C=CC=1C(F)C(CC1)CCN1C(=O)C(C=N1)=CC=C1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 FJNHSBVZTQFKEF-UHFFFAOYSA-N 0.000 claims 1
- CINVMDLCMBUCQO-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-cyclopropylsulfonylphenoxy)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(=O)(=O)C2CC2)N=CC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 CINVMDLCMBUCQO-UHFFFAOYSA-N 0.000 claims 1
- JZZXYUGABUNNTJ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-fluorophenyl)sulfonylpiperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 JZZXYUGABUNNTJ-UHFFFAOYSA-N 0.000 claims 1
- PNQUXRANYGABJB-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxy-2-nitrophenoxy)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 PNQUXRANYGABJB-UHFFFAOYSA-N 0.000 claims 1
- FRYJAPPODQHJRU-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]-n-methylpyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N(C)C2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 FRYJAPPODQHJRU-UHFFFAOYSA-N 0.000 claims 1
- ZLENIQODLNSTCZ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridazine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 ZLENIQODLNSTCZ-UHFFFAOYSA-N 0.000 claims 1
- PDHJZIQJMYUJNZ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]pyridazine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C=2N=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 PDHJZIQJMYUJNZ-UHFFFAOYSA-N 0.000 claims 1
- USKHWBFFPMZFMQ-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[2-(dimethylamino)-4-methoxyphenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound CN(C)C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 USKHWBFFPMZFMQ-UHFFFAOYSA-N 0.000 claims 1
- DNOOJFBSTXDBIH-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(4-methylpiperazin-1-yl)benzoyl]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)C2CCN(CC2)C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)C=C1 DNOOJFBSTXDBIH-UHFFFAOYSA-N 0.000 claims 1
- MPYZAJHIMPJCAB-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(cyclopropanecarbonylamino)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C(N=C1)=CC=C1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 MPYZAJHIMPJCAB-UHFFFAOYSA-N 0.000 claims 1
- YQNDTFLKFFIKOY-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-[4-(pentafluoro-$l^{6}-sulfanyl)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(S(F)(F)(F)(F)F)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 YQNDTFLKFFIKOY-UHFFFAOYSA-N 0.000 claims 1
- JPHNAIFCKPLXEH-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 JPHNAIFCKPLXEH-UHFFFAOYSA-N 0.000 claims 1
- WETBWPNUDSHYAH-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 WETBWPNUDSHYAH-UHFFFAOYSA-N 0.000 claims 1
- LNDMBSSQDKPZBK-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-methylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 LNDMBSSQDKPZBK-UHFFFAOYSA-N 0.000 claims 1
- UWFMRHLPQYNROO-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-5-[4-(4-methylphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 UWFMRHLPQYNROO-UHFFFAOYSA-N 0.000 claims 1
- RVROKBCZVIZYLZ-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-5-[4-[4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)C(F)(F)F)CC1 RVROKBCZVIZYLZ-UHFFFAOYSA-N 0.000 claims 1
- RMZUHPQXWRXPOP-UHFFFAOYSA-N n-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-5-[4-(4-methylphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(C)=CC=2)CC1 RMZUHPQXWRXPOP-UHFFFAOYSA-N 0.000 claims 1
- MZWKXTIWRUKNLP-UHFFFAOYSA-N n-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-6-[4-[4-(pentafluoro-$l^{6}-sulfanyl)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(F)(F)(F)(F)F)CC1 MZWKXTIWRUKNLP-UHFFFAOYSA-N 0.000 claims 1
- PJUPLDXIIBQNBZ-UHFFFAOYSA-N n-[1-[2-(4-cyanophenyl)propan-2-yl]piperidin-4-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C(C)(C)N(CC1)CCC1NC(=O)C(N=C1)=CC=C1C(=O)N(CC1)CCN1CC1=CC=C(F)C=C1 PJUPLDXIIBQNBZ-UHFFFAOYSA-N 0.000 claims 1
- MJFMCJRNWDTCIF-UHFFFAOYSA-N n-[1-[[4-(dimethylcarbamoyl)phenyl]methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C(=O)N(C)C)CC2)CC1 MJFMCJRNWDTCIF-UHFFFAOYSA-N 0.000 claims 1
- HVUHUGNDUZGZJI-NVVQJRFUSA-N n-[1-[[4-[3-[2-[2-[2-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]propanoylamino]phenyl]methyl]piperidin-4-yl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(NC(=O)CCOCCOCCOCCNC(=O)CCCC[C@H]4[C@H]5NC(=O)N[C@H]5CS4)=CC=3)CC2)CC1 HVUHUGNDUZGZJI-NVVQJRFUSA-N 0.000 claims 1
- BIPLDIXMEWFTMU-UHFFFAOYSA-N n-[2-[(4-cyanophenyl)methyl]-3,4-dihydro-1h-isoquinolin-7-yl]-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=C3CN(CC=4C=CC(=CC=4)C#N)CCC3=CC=2)CC1 BIPLDIXMEWFTMU-UHFFFAOYSA-N 0.000 claims 1
- RRLULESDYPQECY-YTZIBCIGSA-N n-[4-(4-cyanophenoxy)cyclohexyl]-5-[(3s)-3-(4-fluorophenoxy)pyrrolidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1O[C@@H]1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCC(CC2)OC=2C=CC(=CC=2)C#N)CC1 RRLULESDYPQECY-YTZIBCIGSA-N 0.000 claims 1
- DDXGSXLONGRSHS-UHFFFAOYSA-N n-[4-[(4-cyanophenyl)methyl]cyclohexyl]-6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=C(C=CC=2)C(=O)NC2CCC(CC=3C=CC(=CC=3)C#N)CC2)CC1 DDXGSXLONGRSHS-UHFFFAOYSA-N 0.000 claims 1
- OWQAWPLCNSFMKM-UHFFFAOYSA-N n-[5-(4-cyanophenoxy)pyridin-2-yl]-6-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2N=CC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 OWQAWPLCNSFMKM-UHFFFAOYSA-N 0.000 claims 1
- MHVPPJHUAXVIGF-UHFFFAOYSA-N n-[5-(4-cyanophenoxy)pyridin-2-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2N=CC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 MHVPPJHUAXVIGF-UHFFFAOYSA-N 0.000 claims 1
- RVMRUZKLKWZPBU-UHFFFAOYSA-N n-[5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridin-2-yl]-4-phenylbenzamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC(=O)C=3C=CC(=CC=3)C=3C=CC=CC=3)=CC=2)CC1 RVMRUZKLKWZPBU-UHFFFAOYSA-N 0.000 claims 1
- GKRIJBBPXCVYRF-UHFFFAOYSA-N n-[6-(4-acetylphenoxy)pyridin-3-yl]-6-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C(=CC(F)=CC=2)F)N=C1 GKRIJBBPXCVYRF-UHFFFAOYSA-N 0.000 claims 1
- MAJDJUWLOQSGFM-UHFFFAOYSA-N n-[6-(4-acetylphenoxy)pyridin-3-yl]-6-[4-(4-cyclopropylsulfonylphenoxy)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(=O)(=O)C2CC2)N=C1 MAJDJUWLOQSGFM-UHFFFAOYSA-N 0.000 claims 1
- NWALXLHJGKSUHI-UHFFFAOYSA-N n-[6-(4-acetylphenoxy)pyridin-3-yl]-6-[4-(4-fluorophenyl)sulfonylpiperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(F)=CC=2)N=C1 NWALXLHJGKSUHI-UHFFFAOYSA-N 0.000 claims 1
- GVYSRPMXFBVISQ-UHFFFAOYSA-N n-[6-(4-acetylphenoxy)pyridin-3-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C(C)=O)=CC=2)CC1 GVYSRPMXFBVISQ-UHFFFAOYSA-N 0.000 claims 1
- UUWVSSXXHKEBGA-UHFFFAOYSA-N n-[6-(4-acetylphenoxy)pyridin-3-yl]-6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)N=C1 UUWVSSXXHKEBGA-UHFFFAOYSA-N 0.000 claims 1
- IDAXHXKLJMZMTG-UHFFFAOYSA-N n-[6-(4-acetylphenoxy)pyridin-3-yl]-6-[4-[4-(dimethylcarbamoyl)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C(C)=O)=CC=2)CC1 IDAXHXKLJMZMTG-UHFFFAOYSA-N 0.000 claims 1
- FGKOOCQTYBWAPY-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)-2-methylpyridin-3-yl]-6-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C=1C=C(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)C(=O)C=2C(=CC(F)=CC=2)F)C(C)=NC=1OC1=CC=C(C#N)C=C1 FGKOOCQTYBWAPY-UHFFFAOYSA-N 0.000 claims 1
- YOZDAUSMDOLDJM-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)-2-methylpyridin-3-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C(=NC(OC=3C=CC(=CC=3)C#N)=CC=2)C)CC1 YOZDAUSMDOLDJM-UHFFFAOYSA-N 0.000 claims 1
- MBGUZCQMFZFQCG-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)pyridin-3-yl]-6-[4-(2,4-difluorobenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 MBGUZCQMFZFQCG-UHFFFAOYSA-N 0.000 claims 1
- ZPVFVTXUAVUJPB-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)pyridin-3-yl]-6-[4-(4-fluorophenyl)sulfonylpiperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 ZPVFVTXUAVUJPB-UHFFFAOYSA-N 0.000 claims 1
- NMTSURTYCYXFAT-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)pyridin-3-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 NMTSURTYCYXFAT-UHFFFAOYSA-N 0.000 claims 1
- ZZTBEWMJLPGORM-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)pyridin-3-yl]-6-[4-(4-methylsulfonylphenoxy)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 ZZTBEWMJLPGORM-UHFFFAOYSA-N 0.000 claims 1
- LFRYTBJZABLZSQ-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)pyridin-3-yl]-6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 LFRYTBJZABLZSQ-UHFFFAOYSA-N 0.000 claims 1
- GEWONQLQWOVJJA-UHFFFAOYSA-N n-[6-(4-cyanophenoxy)pyridin-3-yl]-6-[4-[4-(pentafluoro-$l^{6}-sulfanyl)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(S(F)(F)(F)(F)F)=CC=C1OC1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC1 GEWONQLQWOVJJA-UHFFFAOYSA-N 0.000 claims 1
- IOMURNIMMPXUFN-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyrazine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=NC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 IOMURNIMMPXUFN-UHFFFAOYSA-N 0.000 claims 1
- LFVWKMPSGSNUPO-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 LFVWKMPSGSNUPO-UHFFFAOYSA-N 0.000 claims 1
- UFHBGTJZBONLAE-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 UFHBGTJZBONLAE-UHFFFAOYSA-N 0.000 claims 1
- KQQWQTMZKXZLSA-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-methylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1C(=O)C1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 KQQWQTMZKXZLSA-UHFFFAOYSA-N 0.000 claims 1
- YYUWHTNNPRUOTQ-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-methylphenoxy)piperidine-1-carbonyl]pyrazine-2-carboxamide Chemical compound C1=CC(C)=CC=C1OC1CCN(C(=O)C=2N=CC(=NC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 YYUWHTNNPRUOTQ-UHFFFAOYSA-N 0.000 claims 1
- BNYMQAJOSJXUFB-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-methylphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 BNYMQAJOSJXUFB-UHFFFAOYSA-N 0.000 claims 1
- GMARCTCAIUDFNX-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-morpholin-4-ylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCOCC2)C=N1 GMARCTCAIUDFNX-UHFFFAOYSA-N 0.000 claims 1
- STPZXMKMNKFXAI-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-5-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)C=N1 STPZXMKMNKFXAI-UHFFFAOYSA-N 0.000 claims 1
- AECCUDKFJGLGKU-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-6-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)N=C1 AECCUDKFJGLGKU-UHFFFAOYSA-N 0.000 claims 1
- CSSYEVQJDFHNJP-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-6-[4-[4-(4-methylpiperazin-1-yl)benzoyl]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=O)C2CCN(CC2)C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)C=C1 CSSYEVQJDFHNJP-UHFFFAOYSA-N 0.000 claims 1
- BPLWMEIZMICBAU-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-6-[4-[4-(pentafluoro-$l^{6}-sulfanyl)phenoxy]piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1OC(N=C1)=CC=C1NC(=O)C1=CC=C(C(=O)N2CCC(CC2)OC=2C=CC(=CC=2)S(F)(F)(F)(F)F)N=C1 BPLWMEIZMICBAU-UHFFFAOYSA-N 0.000 claims 1
- HSERFCLBNQCVPF-UHFFFAOYSA-N n-[6-(4-fluorophenyl)sulfonylpyridin-3-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(=CC=2)S(=O)(=O)C=2C=CC(F)=CC=2)CC1 HSERFCLBNQCVPF-UHFFFAOYSA-N 0.000 claims 1
- HIHGKUXVUVLGOQ-UHFFFAOYSA-N n-[6-[4-(dimethylcarbamoyl)phenoxy]pyridin-3-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(=CC=3)C(=O)N(C)C)=CC=2)CC1 HIHGKUXVUVLGOQ-UHFFFAOYSA-N 0.000 claims 1
- LYNNCHNXFHBVFJ-UHFFFAOYSA-N n-benzyl-5-(4-benzylpiperazine-1-carbonyl)pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCN(CC=3C=CC=CC=3)CC2)C=NC=1C(=O)NCC1=CC=CC=C1 LYNNCHNXFHBVFJ-UHFFFAOYSA-N 0.000 claims 1
- SFBUXGKMWDVQSW-UHFFFAOYSA-N n-benzyl-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NCC=2C=CC=CC=2)CC1 SFBUXGKMWDVQSW-UHFFFAOYSA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- KHQXBNWTAKPRMR-UHFFFAOYSA-N pyridazine-3,6-dicarboxamide Chemical compound NC(=O)C1=CC=C(C(N)=O)N=N1 KHQXBNWTAKPRMR-UHFFFAOYSA-N 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 abstract description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 115
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 76
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 74
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 50
- 229910052739 hydrogen Inorganic materials 0.000 description 49
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 125000004043 oxo group Chemical group O=* 0.000 description 32
- 229920000728 polyester Polymers 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 125000003386 piperidinyl group Chemical group 0.000 description 28
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 125000001424 substituent group Chemical group 0.000 description 26
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 229910052731 fluorine Inorganic materials 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 239000012267 brine Substances 0.000 description 22
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- 125000004193 piperazinyl group Chemical group 0.000 description 20
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 229910052801 chlorine Inorganic materials 0.000 description 18
- 125000003725 azepanyl group Chemical group 0.000 description 17
- 125000002393 azetidinyl group Chemical group 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 230000006907 apoptotic process Effects 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 102000011690 Adiponectin Human genes 0.000 description 12
- 108010076365 Adiponectin Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 12
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- 239000007821 HATU Substances 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 11
- 229910052717 sulfur Chemical group 0.000 description 11
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 10
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 10
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 10
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 10
- 125000006575 electron-withdrawing group Chemical group 0.000 description 10
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 125000003709 fluoroalkyl group Chemical group 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 102000003808 Adiponectin Receptors Human genes 0.000 description 5
- 108090000179 Adiponectin Receptors Proteins 0.000 description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 5
- 125000004953 trihalomethyl group Chemical group 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- OSSIORZYXTUXBL-UHFFFAOYSA-N 2-methoxycarbonylpyridine-3-carboxylic acid Chemical compound COC(=O)C1=NC=CC=C1C(O)=O OSSIORZYXTUXBL-UHFFFAOYSA-N 0.000 description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 101150028062 Slc17a7 gene Proteins 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 3
- MTJLFBYYTSWTBO-UHFFFAOYSA-N 1-fluoropiperidine Chemical compound FN1CCCCC1 MTJLFBYYTSWTBO-UHFFFAOYSA-N 0.000 description 3
- PEYNABVSERZDTP-UHFFFAOYSA-N 4-[(4-aminopiperidin-1-yl)methyl]benzonitrile;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCN1CC1=CC=C(C#N)C=C1 PEYNABVSERZDTP-UHFFFAOYSA-N 0.000 description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 230000010094 cellular senescence Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 3
- AYASVLHOODXFCY-UHFFFAOYSA-N ethyl 3-chloro-5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxylate Chemical compound C1=C(Cl)C(C(=O)OCC)=NC=C1C(=O)N1CCN(CC=2C=CC(F)=CC=2)CC1 AYASVLHOODXFCY-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 3
- 125000005551 pyridylene group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000004137 sphingolipid metabolism Effects 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- QYJFJNSBTSROEU-UHFFFAOYSA-N (6-bromopyridin-3-yl)-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(Br)=CC=2)CC1 QYJFJNSBTSROEU-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 2
- 150000005525 1-benzylpiperazines Chemical class 0.000 description 2
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 2
- 150000005476 1-benzylpiperidines Chemical class 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- GJHZOKKWVMPWMH-UHFFFAOYSA-N 2-N-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2,5-dicarboxamide Chemical compound N1=C(C=CC(=C1)C(=O)N)C(=O)NC1CCN(CC1)CC1=CC=C(C=C1)C#N GJHZOKKWVMPWMH-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- CJGGKSPGRJHZNP-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyrazine Chemical compound C1=CN=C2NN=NC2=N1 CJGGKSPGRJHZNP-UHFFFAOYSA-N 0.000 description 2
- DVUWFIWQOSNKQJ-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one;sodium Chemical compound [Na].[Na].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 DVUWFIWQOSNKQJ-UHFFFAOYSA-N 0.000 description 2
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 2
- ZIWGQZWSTOEFEP-UHFFFAOYSA-N 3-bromopyridine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=C1Br ZIWGQZWSTOEFEP-UHFFFAOYSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- RTZJEHDLHBLEQT-UHFFFAOYSA-N 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]prop-1-ynyl]pyridine-2-carboxylic acid Chemical compound N1=C(C(O)=O)C(C#CCNC(=O)OC(C)(C)C)=CC(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)=C1 RTZJEHDLHBLEQT-UHFFFAOYSA-N 0.000 description 2
- WAWGIARKAXSRCA-UHFFFAOYSA-N 5-bromo-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]pyridine-2-carboxamide Chemical compound N1=CC(Br)=CC=C1C(=O)NC1CCN(CC=2C=CC(=CC=2)C#N)CC1 WAWGIARKAXSRCA-UHFFFAOYSA-N 0.000 description 2
- NTCKZTBRFXTYBD-UHFFFAOYSA-N 5-methoxycarbonylpyridine-2-carboxylic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)N=C1 NTCKZTBRFXTYBD-UHFFFAOYSA-N 0.000 description 2
- WSBXBQKULKVABI-UHFFFAOYSA-N 6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)=N1 WSBXBQKULKVABI-UHFFFAOYSA-N 0.000 description 2
- IBAMVSKUZJBDDT-UHFFFAOYSA-N 6-[[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]carbamoyl]pyridine-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1CN1CCC(NC(=O)C=2N=CC(=CC=2)C(O)=O)CC1 IBAMVSKUZJBDDT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 2
- 101100191244 Caenorhabditis elegans pph-6 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000006136 Leigh Disease Diseases 0.000 description 2
- 208000017507 Leigh syndrome Diseases 0.000 description 2
- 208000035177 MELAS Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000001721 carboxyacetyl group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 2
- 239000012971 dimethylpiperazine Substances 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- RJANCMBBGWNXBV-UHFFFAOYSA-N methyl 6-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C(=O)N2CCN(CC=3C=CC(F)=CC=3)CC2)=N1 RJANCMBBGWNXBV-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- 125000005554 pyridyloxy group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000006934 radiodermatitis Diseases 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000005556 thienylene group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- RTOXXAQGSJQXIZ-UHFFFAOYSA-N (2-ethyloxolan-3-yl)methanol Chemical compound CCC1OCCC1CO RTOXXAQGSJQXIZ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YMJRDZSVSJUACX-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-phenylmethanone Chemical class C1CC(N)CCN1C(=O)C1=CC=CC=C1 YMJRDZSVSJUACX-UHFFFAOYSA-N 0.000 description 1
- DMJHEIDWSIAXCS-UHFFFAOYSA-N (4-phenylmethoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 DMJHEIDWSIAXCS-UHFFFAOYSA-N 0.000 description 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- YCUKILJYEUDNBJ-UHFFFAOYSA-N 1-(trifluoromethoxy)piperidine Chemical compound FC(F)(F)ON1CCCCC1 YCUKILJYEUDNBJ-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- DAJIDPHYYLRIGK-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]piperidine;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1CN1CCCCC1 DAJIDPHYYLRIGK-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- BOTBFZOLULDADO-UHFFFAOYSA-N 1-benzylpiperidine-2-carbonitrile Chemical compound N#CC1CCCCN1CC1=CC=CC=C1 BOTBFZOLULDADO-UHFFFAOYSA-N 0.000 description 1
- ARYICIJWHSZXTO-UHFFFAOYSA-N 1-benzylpiperidine-4-carboxamide Chemical class C1CC(C(=O)N)CCN1CC1=CC=CC=C1 ARYICIJWHSZXTO-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- VSLLIPMVHAWQJQ-UHFFFAOYSA-N 1-tert-butyl-3-fluoropiperidin-4-amine Chemical compound CC(C)(C)N1CCC(N)C(F)C1 VSLLIPMVHAWQJQ-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- JJJLSDKGRDVLMD-UHFFFAOYSA-N 2H-1,3-oxazol-2-ide Chemical compound O1[C-]=NC=C1 JJJLSDKGRDVLMD-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- VUXHWLMAPJVPNQ-UHFFFAOYSA-N 3,5-dinitro-n-(1,2,3,4-tetrahydrophenanthren-4-yl)benzamide Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC(C(=O)NC2C3=C4C=CC=CC4=CC=C3CCC2)=C1 VUXHWLMAPJVPNQ-UHFFFAOYSA-N 0.000 description 1
- SKMKJBYBPYBDMN-RYUDHWBXSA-N 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1=C(OC(F)F)C(N)=NC=C1C1=CC(N2[C@H]3C[C@H](OC3)C2)=NC(N2CC(F)(F)CC2)=N1 SKMKJBYBPYBDMN-RYUDHWBXSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- TZZDVPMABRWKIZ-MFTLXVFQSA-N 3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-MFTLXVFQSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- HQHTWOUEFQKMAQ-UHFFFAOYSA-N 3-chloropyridine-2-carboxamide Chemical class NC(=O)C1=NC=CC=C1Cl HQHTWOUEFQKMAQ-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- KJQGRZNVKNWQKK-UHFFFAOYSA-N 4-bromopyridine-2,3-dicarboxylic acid Chemical compound OC(=O)C1=NC=CC(Br)=C1C(O)=O KJQGRZNVKNWQKK-UHFFFAOYSA-N 0.000 description 1
- LLWNCLPVMZFQMG-UHFFFAOYSA-N 4-chloro-2-ethoxycarbonylpyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=NC=CC(Cl)=C1C(O)=O LLWNCLPVMZFQMG-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- KBYPITRKIJKGMD-UHFFFAOYSA-N 4-phenoxypiperidine Chemical class C1CNCCC1OC1=CC=CC=C1 KBYPITRKIJKGMD-UHFFFAOYSA-N 0.000 description 1
- DRIREFRFHFBPIN-UHFFFAOYSA-N 4-piperidin-4-yloxybenzonitrile Chemical compound C1=CC(C#N)=CC=C1OC1CCNCC1 DRIREFRFHFBPIN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- MNNQIBXLAHVDDL-UHFFFAOYSA-N 5-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)C=N1 MNNQIBXLAHVDDL-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- UDGFFHKENYPIQD-UHFFFAOYSA-N 5-chloro-6-ethoxycarbonylpyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=NC=C(C(O)=O)C=C1Cl UDGFFHKENYPIQD-UHFFFAOYSA-N 0.000 description 1
- YZSCPLGKKMSBMV-UHFFFAOYSA-N 5-fluoro-4-(8-fluoro-4-propan-2-yl-2,3-dihydro-1,4-benzoxazin-6-yl)-N-[5-(1-methylpiperidin-4-yl)pyridin-2-yl]pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)C1CCN(CC1)C)C1=CC2=C(OCCN2C(C)C)C(=C1)F YZSCPLGKKMSBMV-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- SYZOFRXZMALRGI-JYJNAYRXSA-N CC1=C(NCC(F)(F)F)C(=O)N(C=C1)[C@@H](CC1CC1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C#N Chemical compound CC1=C(NCC(F)(F)F)C(=O)N(C=C1)[C@@H](CC1CC1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C#N SYZOFRXZMALRGI-JYJNAYRXSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 101100191238 Caenorhabditis elegans pph-5 gene Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010017573 Ceramide kinase Proteins 0.000 description 1
- 102100036158 Ceramide kinase Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- UYUVRXBIURTUTG-UHFFFAOYSA-N Cl.Cl.Cl.NC(=O)c1ccccn1 Chemical compound Cl.Cl.Cl.NC(=O)c1ccccn1 UYUVRXBIURTUTG-UHFFFAOYSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- LEUSDRGCPVXECX-FICMROCWSA-N N-[(3R)-1-[(4-cyanophenyl)methyl]-3-fluoropiperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2[C@@H](CN(CC=3C=CC(=CC=3)C#N)CC2)F)CC1 LEUSDRGCPVXECX-FICMROCWSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- IDNTUUFQESKWJF-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[6-(4-phenylanilino)pyridin-3-yl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=NC(NC=3C=CC(=CC=3)C=3C=CC=CC=3)=CC=2)CC1 IDNTUUFQESKWJF-UHFFFAOYSA-N 0.000 description 1
- DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical compound [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 description 1
- UOWHCAKKYIRMSX-UHFFFAOYSA-N [N].C1CNC1 Chemical compound [N].C1CNC1 UOWHCAKKYIRMSX-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- VCVQZESDOBTOFO-UHFFFAOYSA-N [bromo(trifluoromethoxy)methyl]benzene Chemical compound FC(F)(F)OC(Br)C1=CC=CC=C1 VCVQZESDOBTOFO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 125000005992 dihydrobenzisothiazinyl group Chemical group 0.000 description 1
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- NQKNXGHYYQVTNA-UHFFFAOYSA-N ethyl 5-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]-3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]prop-1-ynyl]pyridine-2-carboxylate Chemical compound C1=C(C#CCNC(=O)OC(C)(C)C)C(C(=O)OCC)=NC=C1C(=O)N1CCN(CC=2C=CC(F)=CC=2)CC1 NQKNXGHYYQVTNA-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000005994 isobenzotetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005995 isobenzotetrahydrothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- UXINAUNKRLXXGM-UHFFFAOYSA-N methyl 6-[[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]carbamoyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C(=O)NC1CCN(CC=2C=CC(OC)=CC=2)CC1 UXINAUNKRLXXGM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 description 1
- LEUSDRGCPVXECX-FQLXRVMXSA-N n-[(3r,4r)-1-[(4-cyanophenyl)methyl]-3-fluoropiperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@@H](CN(CC=3C=CC(=CC=3)C#N)CC2)F)CC1 LEUSDRGCPVXECX-FQLXRVMXSA-N 0.000 description 1
- MPRAAOIVYGMJKJ-FIRIVFDPSA-N n-[(3r,4r)-3-fluoro-1-[(4-propan-2-yloxyphenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@@H](CN(CC=3C=CC(OC(C)C)=CC=3)CC2)F)CC1 MPRAAOIVYGMJKJ-FIRIVFDPSA-N 0.000 description 1
- GMBOADRJUJIWFX-ROJLCIKYSA-N n-[(3r,4r)-3-fluoro-1-[(4-pyrrolidin-1-ylphenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@@H](CN(CC=3C=CC(=CC=3)N3CCCC3)CC2)F)CC1 GMBOADRJUJIWFX-ROJLCIKYSA-N 0.000 description 1
- HWOSDYNCBXZMQP-VSGBNLITSA-N n-[(3r,4r)-3-fluoro-1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)N[C@H]2[C@@H](CN(CC=3C=CC(OC(F)(F)F)=CC=3)CC2)F)CC1 HWOSDYNCBXZMQP-VSGBNLITSA-N 0.000 description 1
- SWDLJAZQRMNAGX-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[3-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(F)=CC=C1CC1CN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CCC1 SWDLJAZQRMNAGX-UHFFFAOYSA-N 0.000 description 1
- OFPXCBKYWWZZGT-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-methoxyphenoxy)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 OFPXCBKYWWZZGT-UHFFFAOYSA-N 0.000 description 1
- UXNBFMGMBOACEC-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C=1C=C(C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)C=NC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 UXNBFMGMBOACEC-UHFFFAOYSA-N 0.000 description 1
- SBPPXQVCQDZTHN-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[(3-methoxyphenyl)methyl]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound COC1=CC=CC(CC2CCN(CC2)C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)=C1 SBPPXQVCQDZTHN-UHFFFAOYSA-N 0.000 description 1
- GAXYQFRRJQSHAN-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-[4-[(4-methylphenyl)methyl]piperidine-1-carbonyl]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1CC1CCN(C(=O)C=2C=NC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 GAXYQFRRJQSHAN-UHFFFAOYSA-N 0.000 description 1
- JKGJLUCJLNJXKG-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(=CC=3)C#N)CC2)CC1 JKGJLUCJLNJXKG-UHFFFAOYSA-N 0.000 description 1
- KNIWBJVPMSYDST-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC(F)=CC=3)CC2)CC1 KNIWBJVPMSYDST-UHFFFAOYSA-N 0.000 description 1
- LLRSNVNZYTWKPN-UHFFFAOYSA-N n-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-6-[4-(4-pyrrolidin-1-ylbenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CCC(NC(=O)C=2C=NC(=CC=2)C(=O)N2CCC(CC2)C(=O)C=2C=CC(=CC=2)N2CCCC2)CC1 LLRSNVNZYTWKPN-UHFFFAOYSA-N 0.000 description 1
- XYFIPKRIPGHVQF-UHFFFAOYSA-N n-[6-(4-fluorophenoxy)pyridin-3-yl]-6-[4-(4-methoxybenzoyl)piperidine-1-carbonyl]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C=2N=CC(=CC=2)C(=O)NC=2C=NC(OC=3C=CC(F)=CC=3)=CC=2)CC1 XYFIPKRIPGHVQF-UHFFFAOYSA-N 0.000 description 1
- QACOELYINOMVBY-UHFFFAOYSA-N n-benzylpiperidin-1-amine Chemical compound C=1C=CC=CC=1CNN1CCCCC1 QACOELYINOMVBY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000005876 negative regulation of fatty acid oxidation Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940074355 nitric acid Drugs 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 201000003841 peripheral retinal degeneration Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DDRCHUGHUHZNKZ-UHFFFAOYSA-N phenyl(piperidin-4-yl)methanone Chemical class C=1C=CC=CC=1C(=O)C1CCNCC1 DDRCHUGHUHZNKZ-UHFFFAOYSA-N 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N pyridinedicarboxylic acid Natural products OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010035597 sphingosine kinase Proteins 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZQRYPCAUVKVMLZ-UHFFFAOYSA-N tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)C(F)C1 ZQRYPCAUVKVMLZ-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000005559 triazolylene group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
Description
本出願は、2010年7月29日に出願された米国仮特許出願第61/368,928号の出願日遡及の利益を主張するものであり、この仮特許出願は、全体が参照により本明細書に援用される。
本開示は、一般に、化合物、医薬組成物ならびに化合物およびそれらを含有する組成物の使用方法に関する。本開示は、より詳細には、特定の置換ピリジン化合物およびその医薬組成物、ならびに特定の置換ピリジン化合物を用いた、II型糖尿病、アテローム性動脈硬化症および心血管疾患などの代謝異常を治療および予防する方法に関する。
キナーゼ5'−AMP活性化プロテインキナーゼ(AMPK)は、細胞エネルギー恒常性の重要なセンサーおよびレギュレータとして十分に確立されている。AMPKは、多基質酵素であるため、グルコース輸送、解糖および脂質代謝などの様々な代謝過程を調節する。AMPKは、細胞エネルギー恒常性のセンサーとして働き、特定のホルモンおよび筋収縮ならびに運動、虚血、低酸素症および栄養枯渇などの細胞内の代謝ストレス信号に応答して活性化される。AMPKは、活性化されると、異化経路(脂肪酸の酸化および解糖など)をオンにし、ATP消費経路(脂質生成など)をオフにする。AMPK経路の活性化は、脂肪細胞および筋肉におけるグルコース取り込みを直接刺激することによって、ならびに肝臓および筋肉における脂肪酸の酸化を増加させることによって、インスリン感受性を向上させ、循環脂肪酸レベルを低下させ、細胞内トリグリセリド含量を減少させる。さらに、AMPK経路の活性化は、グリコーゲン合成酵素の活性を低下させることによって、グリコーゲン濃度を低下させる。AMPK経路の活性化は、炎症およびアテローム性動脈硬化症を予防する役割も果たす。AMPK経路の活性化は、血管内皮細胞中の接着分子の発現およびマクロファージからのサイトカイン産生を抑制することで、アテローム性動脈硬化症の初期段階に発生する炎症過程を阻害する。
構造式(I)
D1、D2およびD3の0個または1個がNであり、その他が独立してCH、またはw個のR3の1つによって置換されたCであり;
Eが、−R2、−C(O)NR1R2、−NR1R2または−NR1C(O)R2であり、ここで、R1およびR2が、それらが結合される窒素と一緒にHcaを形成するか、またはR1が、H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)または−C(O)O−(C1〜C4アルキル)であり、R2が、−C(O)Hca、−(C0〜C3アルキル)−Ar、−(C0〜C3アルキル)−Het、−(C0〜C3アルキル)−Cakまたは−(C0〜C3アルキル)−Hcaであり;
各R3が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され;
wが、0、1、2または3であり;
各R4が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され、同じ炭素上の2つのR4が結合してオキソを形成してもよく、異なる炭素上の2つのR4が結合して−(C0〜C4アルキレン)−架橋を形成してもよく;
xが、0、1、2、3または4であり;
Jが、存在しないか、−C(O)−、−NR13−、−NR13C(O)−または−C(O)NR13−であり、ここで、R13が、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され;
「B」によって表される環系が、存在しないか、アリーレン、ヘテロアリーレン、
Tが、H、−(C1〜C6アルキル)、−(C1〜C6アルキル)−R23(ここで、R23が、HetまたはArであり、アルキルの1つ以上の非隣接炭素が、−O−または−S−によって置換されていてもよい)、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10または
Qが、−O−(C0〜C3アルキル)−、−S(O)2−、−L−または(C0〜C3アルキル)−であり、ここで、−(C0〜C3アルキル)−の各炭素が、1つまたは2つのR16によって独立して置換されていてもよい)であり;
「A」によって表される環系が、ヘテロアリール、アリール、シクロアルキルまたはヘテロシクロアルキルであり;
各R5が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−N3、−SF5、−NO2および−CNから選択され;
yが、0、1、2、3または4であり;
ここで、
各Lが、独立して、−NR9C(O)O−、−OC(O)NR9−、−NR9C(O)−NR9−、−NR9C(O)S−、−SC(O)NR9−、−NR9C(O)−、−C(O)−NR9−、−NR9C(S)O−、−OC(S)NR9−、−NR9C(S)−NR9−、−NR9C(S)S−、−SC(S)NR9−、−NR9C(S)−、−C(S)NR9−、−SC(O)NR9−、−NR9C(S)−、−S(O)0〜2−、−C(O)O、−OC(O)−、−C(S)O−、−OC(S)−、−C(O)S−、−SC(O)−、−C(S)S−、−SC(S)−、−OC(O)O−、−SC(O)O−、−OC(O)S−、−SC(S)O−、−OC(S)S−、−NR9C(NR2)NR9−、−NR9SO2−、−SO2NR9−および−NR9SO2NR9−から選択され、
各R6、R7、R8およびR10が、独立して、H、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−(C0〜C6アルキル)、−(C0〜C6アルキル)−NR9−(C0〜C6アルキル)、−(C0〜C6アルキル)−O−(C0〜C6アルキル)、−(C0〜C6アルキル)−C(O)−(C0〜C6アルキル)および−(C0〜C6アルキル)−S(O)0〜2−(C0〜C6アルキル)から選択され、
各R9が、独立して、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され、
各Arが、置換されてもよいアリールであり、
各Hetが、置換されてもよいヘテロアリールであり、
各Cakが、置換されてもよいシクロアルキルであり、
各Hcaが、置換されてもよいヘテロシクロアルキルであり、
各アルキルが、置換されていてもよい。
本開示の一態様は、構造式(I):
D1、D2およびD3の0個または1個がNであり、その他が独立してCH、またはw個のR3の1つによって置換されたCであり;
Eが、−R2、−C(O)NR1R2、−NR1R2または−NR1C(O)R2であり、ここで、R1およびR2が、それらが結合される窒素と一緒にHcaを形成し、またはR1が、H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)または−C(O)O−(C1〜C4アルキル)であり、R2が、−C(O)Hca、−(C0〜C3アルキル)−Ar、−(C1〜C3アルキル)−O−Ar、−(C1〜C3アルキル)−O−Het、−(C0〜C3アルキル)−Het、−(C0〜C3アルキル)−Cakまたは−(C0〜C3アルキル)−Hcaであり;
各R3が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され;
wが、0、1、2または3であり;
各R4が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され、同じ炭素上の2つのR4が結合してオキソを形成してもよく、異なる炭素上の2つのR4が結合して−(C0〜C4アルキレン)−架橋を形成してもよく;
xが、0、1、2、3または4であり;
Jが、存在しないか、−C(O)−、−NR13−、−NR13C(O)−または−C(O)NR13−であり、ここで、R13が、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され;
「B」によって表される環系が、存在しないか、アリーレン、ヘテロアリーレン、
Tが、H、−(C1〜C6アルキル)、−(C1〜C6アルキル)−R23(ここで、R23が、HetまたはArであり、アルキルの1つ以上の非隣接炭素が、−O−または−S−によって置換されていてもよい)、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10または
Qが、−O−(C0〜C3アルキル)−、−S(O)2−、−L−または(C0〜C3アルキル)−であり、ここで、−(C0〜C3アルキル)−の各炭素が、1つまたは2つのR16によって独立して置換されていてもよい)であり;
「A」によって表される環系が、ヘテロアリール、アリール、シクロアルキルまたはヘテロシクロアルキルであり;
各R5が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−N3、−SF5、−NO2および−CNから選択され;
yが、0、1、2、3または4であり;
ここで、
各Lが、独立して、−NR9C(O)O−、−OC(O)NR9−、−NR9C(O)−NR9−、−NR9C(O)S−、−SC(O)NR9−、−NR9C(O)−、−C(O)−NR9−、−NR9C(S)O−、−OC(S)NR9−、−NR9C(S)−NR9−、−NR9C(S)S−、−SC(S)NR9−、−NR9C(S)−、−C(S)NR9−、−SC(O)NR9−、−NR9C(S)−、−S(O)0〜2−、−C(O)O、−OC(O)−、−C(S)O−、−OC(S)−、−C(O)S−、−SC(O)−、−C(S)S−、−SC(S)−、−OC(O)O−、−SC(O)O−、−OC(O)S−、−SC(S)O−、−OC(S)S−、−NR9C(NR2)NR9−、−NR9SO2−、−SO2NR9−および−NR9SO2NR9−から選択され、
各R6、R7、R8およびR10が、独立して、H、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−(C0〜C6アルキル)、−(C0〜C6アルキル)−NR9−(C0〜C6アルキル)、−(C0〜C6アルキル)−O−(C0〜C6アルキル)、−(C0〜C6アルキル)−C(O)−(C0〜C6アルキル)および−(C0〜C6アルキル)−S(O)0〜2−(C0〜C6アルキル)から選択され、
各R9が、独立して、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され、
各Arが、置換されてもよいアリールであり、
各Hetが、置換されてもよいヘテロアリールであり、
各Cakが、置換されてもよいシクロアルキルであり、
各Hcaが、置換されてもよいヘテロシクロアルキルであり、
各アルキルが、置換されていてもよい。
Eが、−R2、−C(O)NR1R2、−NR1R2、−NR1C(O)R2であり、ここで、R1およびR2が、それらが結合される窒素と一緒にHcaを形成するか、またはR1が、H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)または−C(O)O−(C1〜C4アルキル)であり、R2が、−C(O)Hca、−(C0〜C3アルキル)−Ar、−(C0〜C3アルキル)−Het、−(C0〜C3アルキル)−Cakまたは−(C0〜C3アルキル)−Hcaであり;
各R3が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され;
wが、0、1、2または3であり;
各R4が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され、同じ炭素上の2つのR4が結合してオキソを形成し;
xが、0、1、2、3または4であり;
Jが、存在しないか、−C(O)−、−NR13−、−NR13C(O)−または−C(O)NR13−であり、ここで、R13が、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され;
「B」によって表される環系が、存在しないか、アリーレン、ヘテロアリーレン、または
Tが、H、−(C1〜C6アルキル)、−(C1〜C6アルキル)−R23(ここで、R23が、HetまたはArであり、アルキルの1つ以上の非隣接炭素が、−O−または−S−によって置換されていてもよい)、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10または
Qが、−O−(C0〜C3アルキル)−、−S(O)2−、−L−または(C0〜C3アルキル)−であり、ここで、−(C0〜C3アルキル)−の各炭素が、1つまたは2つのR16によって独立して置換されていてもよい)であり;
「A」によって表される環系が、ヘテロアリール、アリール、シクロアルキルまたはヘテロシクロアルキルであり;
各R5が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され;
yが、0、1、2、3または4であり;
ここで、
各Lが、独立して、−NR9C(O)O−、−OC(O)NR9−、−NR9C(O)−NR9−、−NR9C(O)S−、−SC(O)NR9−、−NR9C(O)−、−C(O)−NR9−、−NR9C(S)O−、−OC(S)NR9−、−NR9C(S)−NR9−、−NR9C(S)S−、−SC(S)NR9−、−NR9C(S)−、−C(S)NR9−、−SC(O)NR9−、−NR9C(S)−、−S(O)0〜2−、−C(O)O、−OC(O)−、−C(S)O−、−OC(S)−、−C(O)S−、−SC(O)−、−C(S)S−、−SC(S)−、−OC(O)O−、−SC(O)O−、−OC(O)S−、−SC(S)O−、−OC(S)S−、−NR9C(NR2)NR9−、−NR9SO2−、−SO2NR9−および−NR9SO2NR9−から選択され、
各R6、R7、R8およびR10が、独立して、H、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−(C0〜C6アルキル)、−(C0〜C6アルキル)−NR9−(C0〜C6アルキル)、−(C0〜C6アルキル)−O−(C0〜C6アルキル)、−(C0〜C6アルキル)−C(O)−(C0〜C6アルキル)および−(C0〜C6アルキル)−S(O)0〜2−(C0〜C6アルキル)から選択され、
各R9が、独立して、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され、
各Arが、置換されてもよいアリールであり、
各Hetが、置換されてもよいヘテロアリールであり、
各Cakが、置換されてもよいシクロアルキルであり、
各Hcaが、置換されてもよいヘテロシクロアルキルであり、
各アルキルが、置換されていてもよい。
5−(4−(4−シアノベンジル)ピペラジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)ベンジル)ピペラジン−1−カルボニル)ピコリンアミド
(S)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピロリジン−3−イル)ピコリンアミド;
(S)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(ピリジン−4−イルメチル)ピロリジン−3−イル)ピコリンアミド;
(S)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピロリジン−3−イル)ピコリンアミド;
N−(1−(4−クロロベンジル)ピロリジン−3−イル)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)ピコリンアミド;または
5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(4−(トリフルオロメチル)ベンジル)ピロリジン−3−イル)ピコリンアミド
ではない。
以下の化合物を、スキーム1〜7の方法と類似の方法を用いて作製し;場合によっては、例示的な合成手順を提供する。
1−tert−ブチルオキシカルボニル−3−フルオロ−4−アミノピペリジンのカップリング
1−tert−ブチルオキシカルボニル−3,3−ジフルオロ−4−ベンジルアミノピペリジン
上記の様々な化合物の合成に使用するために、(シス)−および(トランス)−tert−ブチル4−アミノ−3−フルオロピペリジン−1−カルボキシレートを、以下のスキームに表されるように調製した。
酵素結合免疫吸着法を用いて、化合物を、AMPKを活性化する能力についてアッセイした。AMPK活性化を測定するための試薬および手順は周知であり、AMPK活性化アッセイ用のキットが市販されている。化合物1〜498のAMPK活性化についてのEC50値が、以下の表2に示され、表中、「A」が0.5μM未満であり;「B」が0.5〜1μMであり;「C」が1〜5μMであり;「D」が5〜10μMであり;「E」が>10μMである。
Claims (91)
- 以下の構造式を有する化合物またはその薬学的に許容できる塩、プロドラッグ、もしくはN−オキシド、またはその溶媒和物もしくは水和物:
D1、D2およびD3の0個または1個がNであり、その他が独立してCH、またはw個のR3の1つによって置換されたCであり;
Eが、−R2、−C(O)NR1R2、−NR1R2または−NR1C(O)R2であり、ここで、R1およびR2が、それらが結合される窒素と一緒にHcaを形成するか、またはR1が、H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)または−C(O)O−(C1〜C4アルキル)であり、R2が、−C(O)Hca、−(C0〜C3アルキル)−Ar、−(C0〜C3アルキル)−Het、−(C0〜C3アルキル)−Cakまたは−(C0〜C3アルキル)−Hcaであり;
各R3が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され;
wが、0、1、2または3であり;
各R4が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、−NO2および−CNから選択され、同じ炭素上の2つのR4が結合してオキソを形成してもよく、異なる炭素上の2つのR4が結合して−(C0〜C4アルキレン)−架橋を形成してもよく;
xが、0、1、2、3または4であり;
Jが、存在しないか、−C(O)−、−NR13−、−NR13C(O)−または−C(O)NR13−であり、ここで、R13が、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され;
「B」によって表される環系が、存在しないか、アリーレン、ヘテロアリーレン、
Tが、H、−(C1〜C6アルキル)、−(C1〜C6アルキル)−R23(ここで、R23が、HetまたはArであり、前記アルキルの1つ以上の非隣接炭素が、−O−または−S−によって置換されてもよい)、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10または
Qが、−O−(C0〜C3アルキル)−、−S(O)2−、−L−または(C0〜C3アルキル)−であり、前記−(C0〜C3アルキル)−の各炭素が、1つまたは2つのR16によってかつ独立して置換されてもよい)であり;
「A」によって表される環系が、ヘテロアリール、アリール、シクロアルキルまたはヘテロシクロアルキルであり;
各R5が、独立して、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−R7、−(C0〜C6アルキル)−NR8R9、−(C0〜C6アルキル)−OR10、−(C0〜C6アルキル)−C(O)R10、−(C0〜C6アルキル)−S(O)0〜2R10、−ハロゲン、N3、−SF5、−NO2および−CNから選択され;
yが、0、1、2、3または4であり;
ここで、
各Lが、独立して、−NR9C(O)O−、−OC(O)NR9−、−NR9C(O)−NR9−、−NR9C(O)S−、−SC(O)NR9−、−NR9C(O)−、−C(O)−NR9−、−NR9C(S)O−、−OC(S)NR9−、−NR9C(S)−NR9−、−NR9C(S)S−、−SC(S)NR9−、−NR9C(S)−、−C(S)NR9−、−SC(O)NR9−、−NR9C(S)−、−S(O)0〜2−、−C(O)O、−OC(O)−、−C(S)O−、−OC(S)−、−C(O)S−、−SC(O)−、−C(S)S−、−SC(S)−、−OC(O)O−、−SC(O)O−、−OC(O)S−、−SC(S)O−、−OC(S)S−、−NR9C(NR2)NR9−、−NR9SO2−、−SO2NR9−および−NR9SO2NR9−から選択され、
各R6、R7、R8およびR10が、独立して、H、−(C1〜C6アルキル)、−(C1〜C6ハロアルキル)、−(C0〜C6アルキル)−Ar、−(C0〜C6アルキル)−Het、−(C0〜C6アルキル)−Cak、−(C0〜C6アルキル)−Hca、−(C0〜C6アルキル)−L−(C0〜C6アルキル)、−(C0〜C6アルキル)−NR9−(C0〜C6アルキル)、−(C0〜C6アルキル)−O−(C0〜C6アルキル)、−(C0〜C6アルキル)−C(O)−(C0〜C6アルキル)および−(C0〜C6アルキル)−S(O)0〜2−(C0〜C6アルキル)から選択され、
各R9が、独立して、−H、−(C1〜C4アルキル)、−C(O)−(C1〜C4アルキル)および−C(O)O−(C1〜C4アルキル)から選択され、
各Arが、置換されてもよいアリールであり、
各Hetが、置換されてもよいヘテロアリールであり、
各Cakが、置換されてもよいシクロアルキルであり、
各Hcaが、置換されてもよいヘテロシクロアルキルであり、
各アルキルが、置換されていてもよい)。 - D1、D2およびD3が独立してCH、または前記w個のR3の1つによって置換されたCである、請求項1に記載の化合物。
- D1がNであり、D2およびD3が独立してCH、または前記w個のR3の1つによって置換されたCであり;またはD3がNであり、D1およびD2が独立してCH、または前記w個のR3の1つによって置換されたCである、請求項1に記載の化合物。
- 2つのR4が一緒にオキソを形成する、請求項1〜4のいずれか一項に記載の化合物。
- 異なる炭素上の2つのR4が、−(C0〜C4アルキレン)−架橋を形成する、請求項1〜4のいずれか一項に記載の化合物。
- 2つのR4が(C1〜C6アルキル)である、請求項1〜5のいずれか一項に記載の化合物。
- xが0である、請求項1〜4のいずれか一項に記載の化合物。
- 「B」によって表される前記環系が、アリーレンまたはヘテロアリーレンである、請求項1〜3のいずれか一項に記載の化合物。
- 「B」によって表される前記環系が存在しない、請求項1〜3のいずれか一項に記載の化合物。
- Jが、−NR13−または−NR13C(O)−である、請求項1〜11のいずれか一項に記載の化合物。
- Jが、−C(O)NR13−または−C(O)−である、請求項1〜12のいずれか一項に記載の化合物。
- Jが存在しない、請求項1〜13のいずれか一項に記載の化合物。
- R2が、少なくとも1個のフッ素で置換されたHcaである、請求項1〜14のいずれか一項に記載の化合物。
- R2が、−C(O)−R22、−S(O)2−R22、−C(O)−Cak、−CH2−Cak、−CH(CH3)−R22、−C(CH3)2−R22、−CH(C(O)−O(C1〜C4アルキル))Hetで置換されたHcaであり、ここで、R22が、ArまたはHetである、請求項1〜15のいずれか一項に記載の化合物。
- R1およびR2が、それらが結合される窒素と一緒にHcaを形成する、請求項1〜14のいずれか一項に記載の化合物。
- R2が、−(C0〜C3アルキル)−Arまたは−(C0〜C3アルキル)−Hetである、請求項1〜14のいずれか一項に記載の化合物。
- R2が−Cakである、請求項1〜14のいずれか一項に記載の化合物。
- Tが、
- Tが、H、−C(O)−(C1〜C6アルキル)または(C1〜C6アルキル)である、請求項1〜24のいずれか一項に記載の化合物。
- X1がNであり、X2、X3およびX4が独立してCH、または前記w個のR3基の1つで置換されたCである、請求項39に記載の化合物。
- 以下の構造式を有する、請求項1〜42のいずれか一項に記載の化合物:
- 以下の構造式を有する、請求項1〜42のいずれか一項に記載の化合物:
- 以下の構造式を有する、請求項1〜42のいずれか一項に記載の化合物:
- 以下の構造式を有する、請求項1〜42のいずれか一項に記載の化合物:
- 以下の構造式を有する、請求項1〜42のいずれか一項に記載の化合物:
- 前記−G−R17部分が、
- R1がHである、請求項1〜53のいずれか一項に記載の化合物。
- wが0である、請求項1〜54のいずれか一項に記載の化合物。
- 5−(4−(4−シアノベンジル)ピペラジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)ベンジル)ピペラジン−1−カルボニル)ピコリンアミド
(S)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピロリジン−3−イル)ピコリンアミド;
(S)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(ピリジン−4−イルメチル)ピロリジン−3−イル)ピコリンアミド;
(S)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピロリジン−3−イル)ピコリンアミド;
N−(1−(4−クロロベンジル)ピロリジン−3−イル)−5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)ピコリンアミド;または
5−(4−(4−クロロフェニル)ピペラジン−1−カルボニル)−N−(1−(4−(トリフルオロメチル)ベンジル)ピロリジン−3−イル)ピコリンアミドではない、請求項1〜55のいずれか一項に記載の化合物。 - N−(4−(4−シアノベンジル)ピペラジン−4−イル)−6−(4−(4−フルオロベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(ピペラジン−1−カルボニル)ピコリンアミド;
ピリジン−2,5−ジイルビス((4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン);
N−(1−(4−シアノベンゾイル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N2−(1−(4−シアノベンジル)ピペリジン−4−イル)−N5−(3−ベンジルフェニル)ピリジン−2,5−ジカルボキサミド;
N−(4−((4−シアノフェニル)スルホニル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(シクロヘキサンカルボニル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(ベンゾイル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)−1H−ピラゾール−3−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(4−ベンジルフェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル−N−(4−フェニルフェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル−N−(3−フェニルフェニル)ピコリンアミド;
N−(1−(シクロヘキシルメチル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(フェニル)ピペリジン−4−イル)ピコリンアミド;
4−((8−(5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリノイル)−2,8−ジアザスピロ[4.5]デカン−2−イル)メチル)ベンゾニトリル;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−フェノキシフェニル)ピコリンアミド;
(4−(4−フルオロベンジル)ピペラジン−1−イル)(6−(4−(ベンジルオキシ)フェニル)ピリジン−3−イル)メタノン;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(1−フェニルエチル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(2−フェニルフェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(4−ニトロフェニル)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(3−フェノキシフェニル)ピコリンアミド;
(6−(3−(ベンジルオキシ)フェニル)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
N−(1−(4−シアノベンジル)−1H−ピラゾール−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(4−(4−シアノフェニル)フェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(4−トリフルオロメチルフェニル)フェニル)ピコリンアミド;
N−(4−ベンゾイルフェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(4−ベンジルオキシフェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(4−ブロモフェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(4−(4−メトキシフェニル)フェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
(6−(4−ベンジルフェニルアミノ)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
4−((2−(5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピリジン−2−イル)−2,8−ジアザスピロ[4.5]デカン−8−イル)メチル)ベンゾニトリル;
N−(4−(3−シアノフェニル)フェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
(6−(3−フェニルフェニルアミノ)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
(4−(4−フルオロベンジル)ピペラジン−1−イル)(6−(4−フェノキシフェニルアミノ)ピリジン−3−イル)メタノン;
(6−(4−(4−シアノベンジルカルバモイル)フェニル)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
(6−(4−(シアノベンジル)ピペリジン−4−イルアミノ)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
(6−(4−フェニルフェニルアミノ)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
N5−(1−(4−シアノベンジル)−1H−ピラゾール−3−イル)−N2−(1−(4−シアノベンジル)ピペリジン−4−イル)ピリジン−2,5−ジカルボキサミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(1H−ピロール−3−イル)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−モルホリノフェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(4−メチルピペラジン−1−イル)フェニル)ピコリンアミド;
(6−(3−(4−シアノベンジルカルバモイル)フェニル)ピリジン−3イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
N5−(1−(4−シアノベンジル)−1H−ピラゾール−4−イル)−N2−(1−(4−シアノベンジル)ピペリジン−4−イル)ピリジン−2,5−ジカルボキサミド;
(6−(1−(4−フルオロベンジル)−1H−ピラゾール−4−イルアミノ)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(1−(4−フルオロベンジル)−1H−ピラゾール−4−イルアミノ)ピコリンアミド;
(6−(1−(4−シアノベンジル)ピペリジン−4−カルボキサミド)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
N−(4−(4−シアノベンジルカルバモイル)フェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
(6−(4−(4−シアノベンジルカルバモイル)フェニルアミノ)ピリジン−3−イル)(4−(4−フルオロベンジル)ピペラジン−1−イル)メタノン;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(4−フルオロ−3−メチルベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−クロロベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−クロロベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(4−メチルフェノキシ)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(4−メトキシフェノキシ)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(3−フルオロフェノキシ)フェニル)ピコリンアミド;
N−(4−(3−シアノフェノキシ)フェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(3−メトキシフェノキシ)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(3−メチルフェノキシ)フェニル)ピコリンアミド;
N−(4−(4−シアノフェノキシ)フェニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(4−フルオロフェノキシ)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(ピリジン−3−イル)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(4−(チオフェン−3−イル)フェニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−(6−(4−シアノフェノキシ)ピリジン−3−イル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−(6−(3−シアノフェノキシ)ピリジン−3−イル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
5−(4−(4−シアノ−2−メトキシフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−フルオロ−4−フルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロ−4−フルオロベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
トランス−N−(4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−ベンジルピペラジン−1−カルボニル)−N−(1−ベンジルピペリジン−4−イル)ピコリンアミド;
ピリジン−2,5−ジイルビス((4−ベンジルピペラジン−1−イル)メタノン);
6−(4−ベンジルピペラジン−1−カルボニル)−N−(1−ベンジルピペリジン−4−イル)ニコチンアミド;
5,5'−(ピペラジン−1,4−ジイルビス(オキソメチレン))ビス(N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド);
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンゾイル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンゾイル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロフェニルスルホニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシフェニルスルホニル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−ベンゾイルピペラジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−ピバロイルピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(フェニルスルホニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(テトラヒドロ−2H−ピラン−4−イル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−イソプロピルピペラジン−1−カルボニル)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(4−((5−メチルイソオキサゾール−3−イル)メチル)ピペラジン−1−カルボニル)ピコリンアミド;
N2,N6−ビス(1−(4−シアノベンジル)ピペリジン−4−イル)ピリジン−2,6−ジカルボキサミド;
N2,N6−ビス(1−(4−フルオロベンジル)ピペリジン−4−イル)ピリジン−2,6−ジカルボキサミド;
(4−(4−フルオロベンジル)ピペラジン−1−イル)(6−(4−フェネチルピペラジン−1−カルボニル)ピリジン−3−イル)メタノン;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(シクロヘキサンカルボニル)ピペラジン−1−カルボニル)ピコリンアミド;
(4−フェネチルピペラジン−1−イル)(5−(4−フェニルピペラジン−1−カルボニル)ピリジン−2−イル)メタノン;
(4−イソプロピルピペラジン−1−イル)(6−(4−フェネチルピペラジン−1−カルボニル)ピリジン−3−イル)メタノン;
ピリジン−2,5−ジイルビス((4−フェネチルピペラジン−1−イル)メタノン);
(4−(4−フルオロベンジル)ピペラジン−1−イル)(6−(4−フェネチルピペラジン−1−カルボニル)ピリジン−2−イル)メタノン;
(4−(4−フルオロベンジル)ピペラジン−1−イル)(6−(4−フェニルピペラジン−1−カルボニル)ピリジン−2−イル)メタノン;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(シクロヘキシルメチル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(4−(ピリジン−4−イル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(4−フェニルピペラジン−1−カルボニル)ピコリンアミド;
エチル2−(4−(5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド)ピペリジン−1−イル)−2−フェニルアセテート;
N−(4−(4−シアノベンジル)シクロヘキシル)−6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
シス−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(シス−3−フルオロピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(ピリジン−4−イルメチル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(シス−3−フルオロ−1−(ピリジン−4−イルメチル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N2−(1−ベンジルピペリジン−4−イル)−N5−(ビフェニル−4−イル)ピリジン−2,5−ジカルボキサミド;
N2−(1−ベンジルピペリジン−4−イル)−N5−(ビフェニル−3−イル)ピリジン−2,5−ジカルボキサミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−フェニルピコリンアミド;
5−(4−ベンジルフェニルアミノ)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(ビフェニル−4−イルアミノ)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−ベンジルピペラジン−1−イル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(2−(4−シアノフェニル)プロパン−2−イル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(3−フェノキシフェニルアミノ)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(4−フェノキシフェニルアミノ)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(ビフェニル−3−イルアミノ)ピコリンアミド;
N−ベンジル−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−ベンジル−5−(4−ベンジルピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
(R)−N−(1−(4−シアノベンジル)ピロリジン−3−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(4'−シアノビフェニル−4−イルアミノ)ピコリンアミド;
N−(1−ベンジルピペリジン−4−イル)−5−(4'−メトキシビフェニル−4−イルアミノ)ピコリンアミド;
5−(1−ベンジル−1H−1,2,3−トリアゾール−4−イル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(1−ベンジル−1H−1,2,3−トリアゾール−4−イル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
(S)−N−(1−(4−シアノベンジル)ピロリジン−3−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−ベンジルピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)−3,3−ジメチルピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(1−フェニルピペリジン−4−イルアミノ)ピコリンアミド;
N−(シス−1−(4−クロロベンジル)−3−フルオロピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−シアノベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(2−(4−シアノベンジル)−1,2,3,4−テトラヒドロイソキノリン−7−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(2−フェニルプロパン−2−イル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−クロロフェニル)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−シアノフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(フルオロ(4−フルオロフェニル)メチル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(1−(4−クロロフェニル)ピペリジン−4−イルアミノ)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(3,5−ジフルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−カルバモイルベンジル)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−((4−フルオロフェニル)(ヒドロキシ)メチル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N2−(2−(4−シアノベンジル)−1,2,3,4−テトラヒドロイソキノリン−7−イル)−N5−(4−フルオロベンジル)ピリジン−2,5−ジカルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メチルベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(3−フルオロ−4−メトキシベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(3−メトキシベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N2−(1−(4−シアノベンジル)ピペリジン−4−イル)−N5−(2−(4−フルオロフェノキシ)エチル)ピリジン−2,5−ジカルボキサミド;
N−(シス−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド
N−(トランス−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−フルオロベンゾイル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−フルオロベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(2−(4−フルオロベンジル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−クロロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(3−シアノフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(3−クロロ−4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(3,4−ジフルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−3−(5,20−ジオキソ−24−((3aS,4S,6aR)−2−オキソヘキサヒドロ−1H−チエノ[3,4−d]イミダゾール−4−イル)−7,10,13,16−テトラオキサ−4,19−ジアザテトラコサ−1−イニル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
tert−ブチル3−(2−(1−(4−シアノベンジル)ピペリジン−4−イルカルバモイル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピリジン−3−イル)プロパ−2−イニルカルバメート;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−シアノフェノキシ)ピペリジン−1−イル)ピコリンアミド;
N2−(1−(4−シアノベンジル)ピペリジン−4−イル)−N5−(1−(4−シアノフェニル)ピペリジン−4−イル)ピリジン−2,5−ジカルボキサミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−((トランス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−((トランス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピリジン−2−イル)ビフェニル−4−カルボキサミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−((トランス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
1−(4−シアノベンジル)−N−(5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピリジン−2−イル)ピペリジン−4−カルボキサミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
1−(4−シアノベンジル)−N−(5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)ピリジン−2−イル)ピペリジン−4−カルボキサミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−((S)−3−(4−フルオロフェノキシ)ピロリジン−1−カルボニル)ピコリンアミド;
N−(5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピリジン−2−イル)−6−(4−フルオロフェノキシ)ニコチンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ピコリンアミド;
(S)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−5−(3−(4−フルオロフェノキシ)ピロリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−((シス)−4−(4−メトキシフェノキシ)シクロヘキシル)ピコリンアミド;
N−((シス)−4−(4−メトキシフェノキシ)シクロヘキシル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−((シス)−4−(4−メトキシフェノキシ)シクロヘキシル)−5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
(4−(4−フルオロベンジル)ピペラジン−1−イル)(6−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−イル)ピリジン−3−イル)メタノン;
4−(1−(5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピリジン−2−イル)ピペリジン−4−イルオキシ)ベンゾニトリル;
(4−(4−フルオロベンジル)ピペラジン−1−イル)(6−(4−(4−メトキシベンゾイル)ピペリジン−1−イル)ピリジン−3−イル)メタノン;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)−N−((シス)−4−(4−(トリフルオロメチル)フェノキシ)シクロヘキシル)ピコリンアミド;
5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−((シス)−4−(4−(トリフルオロメチル)フェノキシ)シクロヘキシル)ピコリンアミド;
5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−((シス)−4−(4−(トリフルオロメチル)フェノキシ)シクロヘキシル)ピコリンアミド;
5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ピコリンアミド;
N−((シス)−4−(4−シアノ−3−フルオロフェノキシ)シクロヘキシル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−((シス)−4−(4−シアノ−3−フルオロフェノキシ)シクロヘキシル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−カルバモイルベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−メトキシベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
5−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピラジン−2−カルボキサミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−シアノフェノキシ)アゼチジン−1−カルボニル)ピコリンアミド;
5−(3−(4−シアノフェノキシ)アゼチジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(メチルスルホニル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(メチルスルホニル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(メチルスルホニル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(メチルスルホンアミド)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(メチルスルホンアミド)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(4−メチルピペラジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ピラジン−2−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−メトキシベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−6−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
6−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−5−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−メトキシベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−メトキシベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(3−メトキシベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(3−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−アジドベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(3−メトキシベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(3−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(4−メチルピペラジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(4−メチルピペラジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−6−(4−(4−(4−メチルピペラジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(シクロプロピルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(シクロプロピルスルホニル)フェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
6−(4−(4−(シクロプロピルスルホニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−(シクロプロピルスルホニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(イソプロピルスルホニル)フェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−((トランス)−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−((トランス)−3−フルオロ−1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−((トランス)−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−((トランス)−3−フルオロ−1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(シクロプロピルスルホニル)フェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチルスルホニル)フェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(シクロプロパンカルボニル)フェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(エチルスルホニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(6−(4−フルオロフェニルスルホニル)ピリジン−3−イル)−5−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロフェニルスルホニル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(2,2,2−トリフルオロアセチル)フェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N2,N5−ビス(1−ベンジルピペリジン−4−イル)ピリジン−2,5−ジカルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−シアノフェノキシ)ピペリジン−1−イル)ピコリンアミド;
5−(4−(4−クロロベンゾイル)ピペリジン−1−イル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(1−(4−シアノフェニル)ピペリジン−4−イルアミノ)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(2−(4−フルオロフェニル)プロパン−2−イル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(ピリジン−4−イルオキシ)ピペリジン−1−カルボニル)ピコリンアミド;
(S)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−フルオロフェノキシ)ピロリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(1−(4−メトキシフェニル)ピペリジン−4−イルアミノ)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(1−(4−フルオロフェニル)ピペリジン−4−イルアミノ)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(3−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
(R)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−フルオロフェノキシ)ピロリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−((トランス)−4−(4−シアノフェノキシ)−3−フルオロピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−((1R,3r,5S)−3−(4−シアノフェノキシ)−8−アザビシクロ[3.2.1]オクタン−8−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(3,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(2,4−ジフルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(ピリジン−3−イルオキシ)ピペリジン−1−カルボニル)ピコリンアミド;
エチル4−(1−(6−(1−(4−シアノベンジル)ピペリジン−4−イルカルバモイル)ニコチノイル)ピペリジン−4−イルオキシ)ベンゾエート;
5−(4−(4−シアノベンジル)ピペラジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−シアノ−2−メトキシフェノキシ)ピペリジン−1−イル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)ピコリンアミド;
tert−ブチル3−(2−(1−(4−シアノベンジル)ピペリジン−4−イルカルバモイル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピリジン−3−イル)プロピルカルバメート;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−3−(5,21−ジオキソ−25−((3aS,4S,6aR)−2−オキソヘキサヒドロ−1H−チエノ[3,4−d]イミダゾール−4−イル)−8,11,14,17−テトラオキサ−4,20−ジアザペンタコシル)−5−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−((S)−3−(4−フルオロフェノキシ)ピロリジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(p−トリルオキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(4−(3,4−ジフルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(3,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)ピコリンアミド;
N−((シス)−4−(3,5−ジフルオロフェノキシ)シクロヘキシル)−5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−((シス)−4−(3,5−ジフルオロフェノキシ)シクロヘキシル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−イル)ピコリンアミド;
5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−((シス)−4−(4−フルオロフェノキシ)シクロヘキシル)ピコリンアミド;
5−(4−(4−フルオロベンゾイル)ピペリジン−1−カルボニル)−N−((シス)−4−(4−フルオロフェノキシ)シクロヘキシル)ピコリンアミド;
N−(2−(4−フルオロフェノキシ)エチル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(2−(4−フルオロフェノキシ)エチル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(3−(4−フルオロベンジルオキシ)アゼチジン−1−カルボニル)ピコリンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−5−(3−(4−フルオロベンジルオキシ)アゼチジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((シス)−4−(4−フルオロフェノキシ)シクロヘキシル)−5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−((シス)−4−(4−フルオロフェノキシ)シクロヘキシル)−5−(4−(4−フルオロフェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(3−(4−シアノフェノキシ)アゼチジン−1−カルボニル)−N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(3−(4−シアノフェニル)−5,6,7,8−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7−カルボニル)−N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)ピコリンアミド;
N−((1s,4s)−4−(4−シアノフェノキシ)シクロヘキシル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((シス)−4−(4−フルオロフェノキシ)シクロヘキシル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(3,5−ジフルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−((シス)−4−(4−フルオロフェノキシ)シクロヘキシル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
5−(4−(3,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(3,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
5−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ピコリンアミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ニコチンアミド;
tert−ブチル4−(6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)ニコチンアミド)ピペリジン−1−カルボキシレート;
6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−モルホリノベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチル)フェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−シアノフェニル)ピペラジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−フルオロフェニル)ピペラジン−1−カルボニル)ピコリンアミド;
5−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
6−(4−(2,4−ジフルオロフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
6−(4−(2,4−ジフルオロフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(2,4−ジフルオロフェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
N−((トランス)−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((トランス)−3−フルオロ−1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−シアノフェノキシ)ピペリジン−1−イル)ピリダジン−3−カルボキサミド;
N−((トランス)−3−フルオロ−1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((トランス)−3−フルオロ−1−(4−イソプロポキシベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((トランス)−1−(4−シアノ−3−フルオロベンジル)−3−フルオロピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(オキサゾール−4−イルメチル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(チアゾール−2−イルメチル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(ジメチルカルバモイル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−アセチルフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
5−(4−(4−アセチルフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
5−(4−(4−(ジメチルカルバモイル)フェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(トリフルオロメチル)フェノキシ)ピペリジン−1−イル)ピリダジン−3−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−イル)ピリダジン−3−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−ニトロフェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−アミノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
6−(4−(4−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホンアミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−5−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
5−(4−(4−シアノベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(ジメチルアミノ)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(17−オキソ−20−((3aS,4S,6aR)−2−オキソヘキサヒドロ−1H−チエノ[3,4−d]イミダゾール−4−イル)−4,7,10,13−テトラオキサ−16−アザイコサンアミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(メチルチオ)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−ニトロベンジル)ピペリジン−4−イル)ニコチンアミド;
1−(4−シアノベンジル)−4−(5−(4−(4−(メチルスルフィニル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド)ピペリジン1−オキシド;
5−(4−(4−(1H−ピラゾール−1−イル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−モルホリノベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシ−2−ニトロフェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−5−(4−(4−モルホリノベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(4−メチルピペラジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(2−アセトアミド−4−メトキシフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(2−アミノ−4−メトキシフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(2−(ジメチルアミノ)−4−メトキシフェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N3,N6−ビス(1−(4−シアノベンジル)ピペリジン−4−イル)ピリダジン−3,6−ジカルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピリダジン−3−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)ピリダジン−3−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシ−2−(メチルスルホンアミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−アセチルフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−アセチルフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−(1H−ピラゾール−1−イル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−(1H−ピラゾール−1−イル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシ−2−(17−オキソ−21−((3aS,4S,6aR)−2−オキソヘキサヒドロ−1H−チエノ[3,4−d]イミダゾール−4−イル)−4,7,10,13−テトラオキサ−16−アザヘニコサンアミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−アセチルフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
N−(1−(4−フルオロベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(4−(4−シアノフェノキシ)シクロヘキシル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピリダジン−3−カルボキサミド;
N−(1−(4−アミノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−アセトアミドベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−アセチルフェノキシ)ピペリジン−1−カルボニル)−N−(4−(4−シアノフェノキシ)シクロヘキシル)ニコチンアミド;
5−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(14−オキソ−18−((3aS,4S,6aR)−2−オキソヘキサヒドロ−1H−チエノ[3,4−d]イミダゾール−4−イル)−4,7,10−トリオキサ−13−アザオクタデカンアミド)ベンジル)ピペリジン−4−イル)ピコリンアミド;
6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(4−フルオロフェニル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(4−メトキシフェニル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
5−(4−(4−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(シクロプロパンカルボキサミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチルチオ)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
6−(4−(3−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(3−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(3−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(3−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(トリフルオロメチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
tert−ブチル3−(5−(1−(4−シアノベンジル)ピペリジン−4−イルカルバモイル)−2−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ピリジン−3−イル)プロピルカルバメート;
N−(1−(4−シアノフェニル)ピペリジン−4−イル)−6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノフェニル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(チオフェン−2−カルボニル)ピペリジン−1−カルボニル)ピコリンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(メチルスルホニル)フェニル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)−N−(1−(4−(メチルスルホニル)フェニル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−フルオロフェニル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−シアノフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシフェニル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(3−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(3−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
N−((3S,4R)−3−フルオロ−1−((5−メチルイソオキサゾール−3−イル)メチル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((3S,4R)−3−フルオロ−1−((2−メチルチアゾール−4−イル)メチル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(3−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(3−アセトアミドフェノキシ)ピペリジン−1−カルボニル)−N−(1−(3−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(3−(シクロプロパンカルボキサミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(3−(シクロプロパンカルボキサミド)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−フルオロベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(3−(シクロプロパンカルボキサミド)フェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−6−(4−(3−(シクロプロパンカルボキサミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(3−(シクロプロパンカルボキサミド)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(トリフルオロメチルチオ)フェノキシ)ピペリジン−1−カルボニル)ピリダジン−3−カルボキサミド;
6−(4−(4−アセチルフェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−シアノベンジル)ピペリジン−4−イル)ピリダジン−3−カルボキサミド;
6−(4−(3−(シクロプロパンカルボキサミド)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−メトキシベンジル)ピペリジン−4−イル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(3−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−((シス)−4−(4−シアノフェノキシ)シクロヘキシル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(3−フルオロ−4−メトキシベンジル)ピペリジン−4−イル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−(ピロリジン−1−イル)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−イソプロポキシベンジル)ピペリジン−4−イル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノ−3−フルオロベンジル)ピペリジン−4−イル)−6−(4−(4−(ピロリジン−1−イル)ベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(シクロプロパンスルホンアミド)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(シクロプロパンスルホンアミド)フェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(トリフルオロメチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−((トランス)−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−6−(4−(4−(トリフルオロメチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−((3R,4R)−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((3S,4S)−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((シス)−1−(4−シアノベンジル)−3−フルオロピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(シクロプロパンカルボニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(シクロプロパンカルボニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(シクロプロパンカルボニル)フェノキシ)ピペリジン−1−カルボニル)−N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)ニコチンアミド;
6−(4−(4−(シクロプロパンカルボニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)ピリジン−3−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)ピリジン−3−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−((シス)−3−フルオロ−1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)ピリジン−3−イル)−6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−(メチルスルホニル)フェノキシ)ピリジン−3−イル)ニコチンアミド;
6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−(メチルスルホニル)フェノキシ)ピリジン−3−イル)ニコチンアミド;
N−(6−(4−フルオロフェニルスルホニル)ピリジン−3−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(5−(4−シアノフェノキシ)ピリジン−2−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(5−(4−シアノフェノキシ)ピリジン−2−イル)−6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−フルオロフェニルスルホニル)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−フルオロフェニルスルホニル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)ピリジン−3−イル)−6−(4−(4−フルオロフェニルスルホニル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−フルオロフェニルスルホニル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−フルオロフェニルスルホニル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−フルオロフェニルスルホニル)ピペリジン−1−カルボニル)−N−(1−(3−メトキシベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)ピリジン−3−イル)−6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−フルオロベンジル)ピペラジン−1−カルボニル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)−2−メチルピリジン−3−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)−2−メチルピリジン−3−イル)−6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−(ジメチルカルバモイル)フェノキシ)ピリジン−3−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(2,4−ジフルオロベンゾイル)ピペリジン−1−カルボニル)−N−(6−(4−(ジメチルカルバモイル)フェノキシ)ピリジン−3−イル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−メチルニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−メチル−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)−N−(1−(4−メトキシベンジル)ピペリジン−4−イル)−N−メチルニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−(メチルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−(シクロプロピルスルホニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−(メチルスルホニル)フェニル)ピペラジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−(ジメチルカルバモイル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−アセチルフェノキシ)ピリジン−3−イル)−6−(4−(4−(イソプロピルスルホニル)フェニル)ピペラジン−1−カルボニル)ニコチンアミド;
N−(1−(4−(ジメチルカルバモイル)ベンジル)ピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−フルオロベンジル)ピペラジン−1−イル)ピリダジン−3−カルボキサミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−5−(4−(4−(ペンタフルオロスルファニル)フェノキシ)ピペリジン−1−カルボニル)ピコリンアミド;
N−(1−(4−シアノベンジル)ピペリジン−4−イル)−6−(4−(4−(ペンタフルオロスルファニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
6−(4−(4−(ペンタフルオロスルファニル)フェノキシ)ピペリジン−1−カルボニル)−N−(1−(4−(トリフルオロメトキシ)ベンジル)ピペリジン−4−イル)ニコチンアミド;
N−(1−(4−メトキシベンジル)ピペリジン−4−イル)−6−(4−(4−(ペンタフルオロスルファニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−フルオロフェノキシ)ピリジン−3−イル)−6−(4−(4−(ペンタフルオロスルファニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;
N−(6−(4−シアノフェノキシ)ピリジン−3−イル)−6−(4−(4−(ペンタフルオロスルファニル)フェノキシ)ピペリジン−1−カルボニル)ニコチンアミド;または
N−(1−(4−シアノベンジル)−3,3−ジフルオロピペリジン−4−イル)−6−(4−(4−メトキシベンゾイル)ピペリジン−1−カルボニル)ニコチンアミドである、請求項1に記載の化合物、
またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物。 - 少なくとも1種の薬学的に許容できる担体、希釈剤または賦形剤;および
請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物を含む、医薬組成物。 - 細胞中のAMPK経路を活性化するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- 細胞中の脂肪酸の酸化を増加させるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- 細胞中のグリコーゲン濃度を低下させるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- 細胞中のグルコース取り込みを増加させるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- 対象におけるトリグリセリドレベルを低下させるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 対象のII型糖尿病を治療するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 対象のアテローム性動脈硬化症または心血管疾患を治療または予防する方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 細胞中のセラミダーゼの機能を上方制御するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- 細胞中のセラミド濃度を低下させるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- 対象における細胞増殖が不十分であるかまたは必要とされる疾患を治療または予防するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 対象におけるセラミドレベルの上昇に関連する疾病を治療または予防するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 対象における酸化的ストレス、ミトコンドリア機能障害、フリーラジカルによる損傷および/または代謝非効率に関連する疾患または病態を治療または改善するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 対象におけるミトコンドリア機能障害の疾患を治療または改善するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 運動不耐性、慢性疲労症候群、筋力低下、ミオクローヌス、ミオクローヌスてんかん、カーンズ・セイヤー症候群、リー病、ミトコンドリア脳筋症・ラクトアシドーシス・脳卒中(MELAS)症候群および脳卒中様症状からなる群から選択される、対象の疾患を治療または改善するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 対象における代謝効率を高めるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象における線維の酸化能、耐久性、有酸素負荷量(aerobic workload)、またはそれらの任意の組合せを高めるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象において運動効率、運動に対する耐久力および/または運動能力を向上させるための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象において運動の効果を模倣するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象の疾患を治療または改善するための方法であって、前記疾患が、低酸素状態、狭心症、冠動脈血管閉塞に続発する冠動脈虚血および臓器障害、間欠性跛行、多発梗塞性認知症、心筋梗塞、脳卒中、高山病および鬱血性心不全を含む心不全からなる群から選択され、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象の筋ジストロフィー状態の改善の治療のための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- デュシェンヌ型筋ジストロフィー、ベッカー型筋ジストロフィー、およびフリードライヒ運動失調症からなる群から選択される、対象の疾患を治療または改善するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 筋線維の酸化能を高めるための方法であって、請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記筋線維を接触させる工程を含む、方法。
- それを必要とする対象における酸化的ストレスを軽減するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象におけるフリーラジカルによる損傷を軽減するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象の疾患または病態を治療または改善するための方法であって、前記疾患または病態は、神経疾患、低酸素状態、虚血、虚血再かん流傷害、心筋虚血または心筋梗塞、脳血管発作、手術による虚血、外傷性出血、蘇生による損傷、脊髄損傷、炎症性疾患、自己免疫疾患、ダウン症、ハレルフォルデン・スパッツ病、ハンチントン舞踏病、ウィルソン病、糖尿病性血管症、ブドウ膜炎、慢性閉塞性肺疾患(COPD)、喘息、新生物形成、クローン病、炎症性腸疾患、膵炎および加齢に伴う疾患からなる群から選択され、前記方法は、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- それを必要とする対象の神経疾患を治療または改善するための方法であって、前記神経疾患は、低下したミトコンドリア機能、酸化的ストレス、または両方に関連し、前記方法は、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する工程を含む、方法。
- 細胞中の酸化的ストレスを軽減するための方法であって、請求項1〜57のいずれか一項に記載の化合物またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- 細胞中のフリーラジカルによる損傷を軽減するための方法であって、請求項1〜57のいずれか一項に記載の化合物またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物と、前記細胞を接触させる工程を含む、方法。
- それを必要とする対象における炎症性疾患または炎症作用を治療するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する化合物を含む、方法。
- それを必要とする対象における肺炎症を治療するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する化合物を含む、方法。
- それを必要とする対象における臓器炎症を治療するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する化合物を含む、方法。
- それを必要とする対象における腎臓または肝臓の炎症を治療するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する化合物を含む、方法。
- それを必要とする対象におけるマクロファージに関連する炎症を治療するための方法であって、有効な量の請求項1〜57のいずれか一項に記載の化合物、またはその薬学的に許容できる塩もしくはN−オキシド、またはその溶媒和物もしくは水和物、あるいは有効な量の請求項58に記載の組成物を、前記対象に投与する化合物を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36892810P | 2010-07-29 | 2010-07-29 | |
US61/368,928 | 2010-07-29 | ||
PCT/US2011/046019 WO2012016217A1 (en) | 2010-07-29 | 2011-07-29 | Ampk-activating heterocyclic compounds and methods for using the same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013532692A true JP2013532692A (ja) | 2013-08-19 |
JP2013532692A5 JP2013532692A5 (ja) | 2014-09-04 |
JP5889895B2 JP5889895B2 (ja) | 2016-03-22 |
Family
ID=44504240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013522013A Expired - Fee Related JP5889895B2 (ja) | 2010-07-29 | 2011-07-29 | Ampk活性化複素環化合物およびその使用方法 |
Country Status (24)
Country | Link |
---|---|
US (8) | US8791136B2 (ja) |
EP (1) | EP2598483B1 (ja) |
JP (1) | JP5889895B2 (ja) |
KR (1) | KR101764952B1 (ja) |
CN (1) | CN103201267B (ja) |
AU (1) | AU2011283684B2 (ja) |
BR (1) | BR112013002112B1 (ja) |
CA (1) | CA2806341C (ja) |
CL (1) | CL2013000261A1 (ja) |
DK (1) | DK2598483T3 (ja) |
EA (1) | EA025611B1 (ja) |
ES (1) | ES2823350T3 (ja) |
HU (1) | HUE052110T2 (ja) |
IL (1) | IL223856A (ja) |
MX (1) | MX338707B (ja) |
MY (1) | MY165584A (ja) |
NZ (1) | NZ605692A (ja) |
PE (1) | PE20130774A1 (ja) |
PL (1) | PL2598483T3 (ja) |
PT (1) | PT2598483T (ja) |
SG (1) | SG186850A1 (ja) |
UA (1) | UA112061C2 (ja) |
WO (1) | WO2012016217A1 (ja) |
ZA (2) | ZA201300374B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015186821A1 (ja) * | 2014-06-06 | 2015-12-10 | アステラス製薬株式会社 | 2-アシルアミノチアゾール誘導体またはその塩 |
JPWO2015046595A1 (ja) * | 2013-09-30 | 2017-03-09 | 国立大学法人 東京大学 | アディポネクチン受容体活性化化合物 |
JP2017507185A (ja) * | 2014-03-06 | 2017-03-16 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドShanghai Haiyan Pharmaceutical Technology Co., Ltd. | オレキシン受容体拮抗剤としてのピペリジン誘導体 |
JP2020514418A (ja) * | 2017-03-15 | 2020-05-21 | ルネラ・バイオテック・インコーポレーテッド | ミトリボシン:癌細胞、細菌、及び病原性酵母を標的とした、ミトコンドリアベースの治療薬 |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007079078A1 (en) | 2005-12-29 | 2007-07-12 | Bayer Schering Pharma Aktiengesellschaft | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
AU2011283684B2 (en) | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
MX360706B (es) | 2011-10-07 | 2018-11-14 | Takeda Pharmaceuticals Co | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
WO2013116491A1 (en) | 2012-02-01 | 2013-08-08 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using them |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
SG10201705662WA (en) | 2013-01-15 | 2017-08-30 | Incyte Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
TWI647227B (zh) * | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | 2-醯胺噻唑衍生物或其鹽 |
RU2686101C2 (ru) | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
RU2737434C2 (ru) | 2013-03-13 | 2020-11-30 | Форма Терапьютикс, Инк. | Новые соединения и композиции для ингибирования fasn |
BR112015022226A2 (pt) | 2013-03-14 | 2017-07-18 | Celtaxsys Inc | inibidores de leucotrieno a4 hidrolase |
CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
WO2014152518A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ampkを活性化させるインダゾール化合物 |
SG11201510125WA (en) | 2013-06-10 | 2016-01-28 | Astellas Pharma Inc | Bicyclic nitrogen-containing aromatic heterocyclic amide compound |
CA2916468C (en) | 2013-07-02 | 2019-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
SG11201602183QA (en) | 2013-10-25 | 2016-05-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
SG11201610476VA (en) | 2014-07-01 | 2017-01-27 | Millennium Pharm Inc | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
CA2959290A1 (en) * | 2014-08-26 | 2016-03-03 | Astellas Pharma Inc. | 2-aminothiazole derivative or salt thereof |
EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
US10189863B2 (en) | 2014-10-10 | 2019-01-29 | Pulmocide Limited | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives |
PL3209655T3 (pl) | 2014-10-24 | 2020-12-28 | Landos Biopharma, Inc. | Leczenie oparte na białku 2 podobnym do syntetazy lantioniny C |
EP3233867B1 (en) | 2014-12-18 | 2018-10-17 | Pulmocide Limited | 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
CN112625028A (zh) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
CA3001799A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
US11001569B2 (en) | 2016-01-22 | 2021-05-11 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors |
AU2017209935B2 (en) | 2016-01-22 | 2021-04-01 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as NIK inhibitors |
EP4108659A1 (en) | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
WO2018002217A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Heteroaromatic derivatives as nik inhibitors |
AU2017296338A1 (en) | 2016-07-14 | 2019-01-03 | Pfizer Inc. | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
CN111148743B (zh) | 2017-10-06 | 2023-12-15 | 福马治疗有限公司 | 抑制泛素特异性肽酶30 |
WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
CA3078769A1 (en) | 2017-10-27 | 2019-05-02 | Boehringer Ingelheim International Gmbh | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. | キナーゼ阻害剤としての複素環式化合物 |
US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
CA3110113A1 (en) | 2018-10-05 | 2020-04-09 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
JP7430852B2 (ja) | 2019-12-20 | 2024-02-14 | エヌイミューン バイオファーマ インコーポレイテッド | ランチオニンc様タンパク質2リガンド、それを用いて調製される細胞、およびそれを使用する療法 |
CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
WO2022072397A1 (en) | 2020-09-30 | 2022-04-07 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
WO2024006297A1 (en) * | 2022-06-28 | 2024-01-04 | Modulation Therapeutics, Inc. | Scd1 inhibitors for treating liver disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008083124A1 (en) * | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
WO2009065131A1 (en) * | 2007-11-16 | 2009-05-22 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
WO2009076631A1 (en) * | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
WO2009132136A1 (en) * | 2008-04-23 | 2009-10-29 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
US20100190802A1 (en) * | 2009-01-28 | 2010-07-29 | Rigel Pharmaceuticals Inc. | Carboxamide compounds and methods for using the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060247227A1 (en) * | 2003-07-18 | 2006-11-02 | Bailey James M | Substituted piperidines as histamine h3 receptor ligands |
WO2005028438A1 (ja) * | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
EP1697307B1 (en) | 2003-12-12 | 2014-03-12 | Eli Lilly & Company | Opioid receptor antagonists |
JP2009527479A (ja) | 2006-02-17 | 2009-07-30 | アバロン ファーマシューティカルズ,インコーポレイテッド | ヒドロキシピペリジン誘導体とその使用 |
EP1932834B1 (en) * | 2006-12-11 | 2011-04-27 | The Genetics Company, Inc. | Aromatic 1,4-DI-Carboxylamides and their use |
BRPI0815572A2 (pt) * | 2007-08-22 | 2015-02-18 | Irm Llc | Compostos e composições como inibidores de quinases |
US8367836B2 (en) * | 2009-04-27 | 2013-02-05 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
AU2011283684B2 (en) | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
WO2013116491A1 (en) * | 2012-02-01 | 2013-08-08 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using them |
-
2011
- 2011-07-29 AU AU2011283684A patent/AU2011283684B2/en not_active Ceased
- 2011-07-29 PT PT117467092T patent/PT2598483T/pt unknown
- 2011-07-29 MY MYPI2013000077A patent/MY165584A/en unknown
- 2011-07-29 BR BR112013002112-8A patent/BR112013002112B1/pt active IP Right Grant
- 2011-07-29 CN CN201180047484.XA patent/CN103201267B/zh active Active
- 2011-07-29 EP EP11746709.2A patent/EP2598483B1/en active Active
- 2011-07-29 US US13/194,810 patent/US8791136B2/en active Active
- 2011-07-29 SG SG2012095964A patent/SG186850A1/en unknown
- 2011-07-29 UA UAA201302459A patent/UA112061C2/uk unknown
- 2011-07-29 WO PCT/US2011/046019 patent/WO2012016217A1/en active Application Filing
- 2011-07-29 PE PE2013000118A patent/PE20130774A1/es active IP Right Grant
- 2011-07-29 PL PL11746709T patent/PL2598483T3/pl unknown
- 2011-07-29 JP JP2013522013A patent/JP5889895B2/ja not_active Expired - Fee Related
- 2011-07-29 DK DK11746709.2T patent/DK2598483T3/da active
- 2011-07-29 HU HUE11746709A patent/HUE052110T2/hu unknown
- 2011-07-29 CA CA2806341A patent/CA2806341C/en active Active
- 2011-07-29 ES ES11746709T patent/ES2823350T3/es active Active
- 2011-07-29 KR KR1020137005054A patent/KR101764952B1/ko active IP Right Grant
- 2011-07-29 NZ NZ605692A patent/NZ605692A/en not_active IP Right Cessation
- 2011-07-29 EA EA201390184A patent/EA025611B1/ru not_active IP Right Cessation
- 2011-07-29 MX MX2013000575A patent/MX338707B/es active IP Right Grant
-
2012
- 2012-12-25 IL IL223856A patent/IL223856A/en active IP Right Grant
-
2013
- 2013-01-15 ZA ZA2013/00374A patent/ZA201300374B/en unknown
- 2013-01-28 CL CL2013000261A patent/CL2013000261A1/es unknown
- 2013-03-13 US US13/801,064 patent/US8980921B2/en active Active
- 2013-03-13 US US13/800,986 patent/US8809370B2/en active Active
- 2013-03-13 US US13/801,030 patent/US8987303B2/en active Active
-
2014
- 2014-03-13 ZA ZA2014/01833A patent/ZA201401833B/en unknown
- 2014-07-08 US US14/325,766 patent/US9266856B2/en not_active Expired - Fee Related
-
2016
- 2016-01-12 US US14/993,936 patent/US9663496B2/en active Active
-
2017
- 2017-05-23 US US15/603,023 patent/US10377742B2/en active Active
-
2019
- 2019-06-25 US US16/451,613 patent/US10941134B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008083124A1 (en) * | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
WO2009065131A1 (en) * | 2007-11-16 | 2009-05-22 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
WO2009076631A1 (en) * | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
WO2009132136A1 (en) * | 2008-04-23 | 2009-10-29 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
US20100190802A1 (en) * | 2009-01-28 | 2010-07-29 | Rigel Pharmaceuticals Inc. | Carboxamide compounds and methods for using the same |
JP5658688B2 (ja) * | 2009-01-28 | 2015-01-28 | ライジェル ファーマシューティカルズ, インコーポレイテッド | カルボキサミド化合物およびその使用方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2015046595A1 (ja) * | 2013-09-30 | 2017-03-09 | 国立大学法人 東京大学 | アディポネクチン受容体活性化化合物 |
JP2017507185A (ja) * | 2014-03-06 | 2017-03-16 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドShanghai Haiyan Pharmaceutical Technology Co., Ltd. | オレキシン受容体拮抗剤としてのピペリジン誘導体 |
WO2015186821A1 (ja) * | 2014-06-06 | 2015-12-10 | アステラス製薬株式会社 | 2-アシルアミノチアゾール誘導体またはその塩 |
JPWO2015186821A1 (ja) * | 2014-06-06 | 2017-04-20 | アステラス製薬株式会社 | 2−アシルアミノチアゾール誘導体またはその塩 |
EA031866B1 (ru) * | 2014-06-06 | 2019-03-29 | Астеллас Фарма Инк. | Производное 2-ациламинотиазола или его соль |
USRE49111E1 (en) | 2014-06-06 | 2022-06-21 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
JP2020514418A (ja) * | 2017-03-15 | 2020-05-21 | ルネラ・バイオテック・インコーポレーテッド | ミトリボシン:癌細胞、細菌、及び病原性酵母を標的とした、ミトコンドリアベースの治療薬 |
JP7104134B2 (ja) | 2017-03-15 | 2022-07-20 | ルネラ・バイオテック・インコーポレーテッド | ミトリボシン:癌細胞、細菌、及び病原性酵母を標的とした、ミトコンドリアベースの治療薬 |
JP7312891B2 (ja) | 2017-03-15 | 2023-07-21 | ルネラ・バイオテック・インコーポレーテッド | ミトリボシン:癌細胞、細菌、及び病原性酵母を標的とした、ミトコンドリアベースの治療薬 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10941134B2 (en) | AMPK-activating heterocyclic compounds and methods for using the same | |
JP5650404B2 (ja) | N−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 | |
JP5544296B2 (ja) | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 | |
JP5650540B2 (ja) | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 | |
AU2010208247B2 (en) | Carboxamide compounds and methods for using the same | |
JP6182602B2 (ja) | 1−[m−カルボキサミド(ヘテロ)アリール−メチル]−ヘテロシクリル−カルボキサミド誘導体 | |
WO2013116491A1 (en) | Carboxamide, sulfonamide and amine compounds and methods for using them | |
AU2012289255A1 (en) | Substituted heterocyclic aza derivatives | |
BRPI0609147A2 (pt) | 1,3-tiazol-5-carboxamidas úteis como agentes quimioterapêuticos de cáncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140718 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140718 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150323 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5889895 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |